WO2010078985A2 - Procédé cosmétique pour réguler le brunissement de la peau induit par un rayonnement uv et compositions - Google Patents

Procédé cosmétique pour réguler le brunissement de la peau induit par un rayonnement uv et compositions Download PDF

Info

Publication number
WO2010078985A2
WO2010078985A2 PCT/EP2009/064908 EP2009064908W WO2010078985A2 WO 2010078985 A2 WO2010078985 A2 WO 2010078985A2 EP 2009064908 W EP2009064908 W EP 2009064908W WO 2010078985 A2 WO2010078985 A2 WO 2010078985A2
Authority
WO
WIPO (PCT)
Prior art keywords
agents
company
acid
name
extract
Prior art date
Application number
PCT/EP2009/064908
Other languages
English (en)
Other versions
WO2010078985A3 (fr
Inventor
Francine Baldo
Didier Candau
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Priority to JP2011541256A priority Critical patent/JP2012512215A/ja
Priority to CN200980156894.0A priority patent/CN102316844B/zh
Publication of WO2010078985A2 publication Critical patent/WO2010078985A2/fr
Publication of WO2010078985A3 publication Critical patent/WO2010078985A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/415—Aminophenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966—Triazines or their condensed derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Definitions

  • the present invention relates to a cosmetic method for controlling the browning of the skin induced by UV radiation, in particular the browning of dark skin, consisting in applying, to the surface of the skin, at least one composition comprising, in a cosmetically acceptable carrier: a) at least one depigmenting agent and b) at least one system for screening out both UVA radiation and UVB radiation; c) and optionally at least one desquamating agent; d) said composition having a critical wavelength ⁇ c of greater than 370 nm.
  • the present invention also relates to a composition
  • a composition comprising, in a cosmetically acceptable carrier : a) at least one depigmenting agent and b) at least one system for screening out both UVA radiation and UVB radiation; c) and optionally at least one desquamating agent; d) said composition having a critical wavelength ⁇ c of greater than 370 nm.
  • a cosmetically acceptable carrier a) at least one depigmenting agent and b) at least one system for screening out both UVA radiation and UVB radiation; c) and optionally at least one desquamating agent; d) said composition having a critical wavelength ⁇ c of greater than 370 nm.
  • Many cosmetic compositions intended to limit the darkening of the skin induced by solar radiation, and more particularly UV radiation have been proposed to date. These products are known to the consumer under the term depigmenting products, or bleaching or even whitening products.
  • compositions based on a depigmenting agent and on UV screening agents for obtaining a more effective control of browning of the skin under UV exposure, and in particular of browning of dark skin, compared with the conventional compositions known from the prior art.
  • compositions comprising, in a cosmetically acceptable carrier: a) at least one depigmenting agent and b) at least one system for screening out both UVA radiation with wavelengths between 320 and 400 nm and UVB radiation with wavelengths between 280 and 320 nm; c) and optionally at least one desquamating agent; said composition having a critical wavelength ⁇ c of greater than 370 nm, better control and better preservation of the skin pigmentation under UV exposure, in particular for dark skin, was obtained.
  • the present invention relates to a cosmetic method for controlling browning of the skin induced by UV radiation, in particular browning of dark skin, consisting in applying, to the surface of the skin, at least one composition comprising, in a cosmetically acceptable carrier: a) at least one depigmenting agent and b) at least one system for screening out both UVA radiation with wavelengths between 320 and 400 nm and UVB radiation with wavelengths between 280 and 320 nm; c) and optionally at least one desquamating agent; said composition having a critical wavelength ⁇ c of greater than 370 nm.
  • the present invention also relates to a composition
  • a composition comprising, in a cosmetically acceptable carrier : a) at least one depigmenting agent and b) at least one system for screening out both UVA radiation with wavelengths between 320 and 400 nm and UVB radiation with wavelengths between 280 and 320 nm; c) and optionally at least one desquamating agent; said composition having a critical wavelength ⁇ c of greater than 370 nm.
  • the term "cosmetically acceptable medium” is intended to mean a carrier compatible with the skin, the nails, the lips, the eyelashes and the eyebrows, which has a pleasant colour, odour and feel and which does not generate unacceptable discomfort (tingling, tautness, redness) that may dissuade the consumer from using this composition comprising such a carrier.
  • system for screening out both UVA radiation and UVB radiation is intended to mean an agent for screening out UVA radiation with wavelengths between 320 and 400 nm and UVB radiation with wavelengths between 280 and 320 nm, constituted of either a mixture of several organic compounds and/or inorganic compounds for screening out said UV radiation, for example a mixture comprising a UVA screening agent and a UVB screening agent, or else an organic compound for screening out both UVA radiation and UVB radiation.
  • vitamin C and derivatives thereof and in particular vitamin CG, vitamin CP and 3-0 ethyl vitamin C; arbutin and derivatives thereof, such as those described in applications EP895779 and EP524109, for instance alpha- and beta-arbutin; hydroquinone; aminophenol derivatives such as those described in applications WO 99/10318 and WO 99/32077, and in particular N-cholesteryloxycarbonyl-para- aminophenol and N-ethyloxycarbonyl-para-aminophenol; iminophenol derivatives such as those described in application WO 99/22707; L-2-oxothiazolidine-4- carboxylic acid or procysteine and also salts or esters thereof; ferulic acid; lucinol and derivatives thereof; kojic acid; resorcinol and esters thereof; tranexamic acid and esters thereof; gentisic acid, homo
  • the amount of depigmenting agent in the compositions of the invention preferably ranges from 0.0001% to 20% by weight, relative to the total weight of the composition, more preferably from 0.001% to 15% by weight, even more preferably from 0.001% to 8%, in particular from 0.01% to 5% by weight, more particularly from 0.01% to 4%, more particularly from 0.01% to 3%, even more particularly from 0.01% to 2%, and more particularly from 0.01% to 1% by weight.
  • a hydroxylated diphenylmethane derivative will be chosen as depigmenting agent.
  • the hydroxylated diphenylmethane derivatives that can be used in the compositions of the invention are preferably chosen from those described in application WO 2004/105736. These compositions have formula (I) below:
  • Ri is chosen from a hydrogen atom, a methyl group, a saturated or unsaturated, linear or branched alkyl chain containing from 2 to 4 carbon atoms, an -OH group and a halogen,
  • R 2 is chosen from a hydrogen atom, a methyl group, and a saturated or unsaturated, linear or branched alkyl chain containing from 2 to 5 carbon atoms
  • R3 is chosen from a methyl group or a saturated or unsaturated, linear or branched alkyl chain containing from 2 to 5 carbon atoms
  • R 4 and R5 are, independently of one another, chosen from a hydrogen atom, a methyl group, a saturated or unsaturated, linear or branched alkyl chain containing from 2 to 5 carbon atoms, an -OH group or a halogen.
  • the -OH, Ri, R 4 and R5 groups may be in the ortho-, meta- or para-position with respect to the bond formed with the carbon linking the two aromatic nuclei to one another.
  • Also included in the compounds of the invention having substituted phenyl groups and for which R2 and R3 are distinct are the S-configuration enantiomer forms, the R-configuration enantiomers or the racemic mixture thereof.
  • R2, R4 and R 5 denote a hydrogen atom; - R3 is a methyl group;
  • the -OH groups are in the ortho- and para-position with respect to the bond formed with the carbon linking the two aromatic nuclei to one another.
  • compositions in accordance with the invention comprise a system for screening out both UVA radiation with wavelengths between 320 and 400 nm and UVB radiation with wavelengths between 280 and 320 nm.
  • the compositions in accordance with the invention should have a critical wavelength ⁇ c of less than 370 nm.
  • the critical wavelength is defined in particular in the publication by B. Diffey: B. L. Diffey - A method for broad spectrum classification sunscreens Intern. Journ. Sci. 16 47-52 [1994] .
  • This publication describes an in vitro spectrophotometric method for classifying photoprotective products. It characterizes the uniformity or the broadening of the spectrum in UVA radiation on the basis of an index called critical 5 length ⁇ c .
  • the critical wavelength is the value at which the integral of the screening composition absorbance spectrum reaches 90% of the integral under the curve. It is defined in the following way:
  • composition It can be readily calculated by means of a conventional spectrophotometer which makes it possible to plot the absorbance curve for the composition of the invention .
  • the photoprotective agent (s) present in the photoprotective agent (s) present in the photoprotective agent (s)
  • screening system in accordance with the invention is (are) chosen from hydrophilic and/or hydrophobic, organic and/or inorganic UV screening agents that are active in the UVA and/or UVB range.
  • the organic UV screening agents are in particular
  • 25 chosen from cinnamic derivatives; anthranilates; salicylic derivatives, dibenzoylmethane derivatives, camphor derivatives; benzophenone derivatives; ⁇ , ⁇ -diphenylacrylate derivatives; triazine derivatives; benzotriazole derivatives; benzalmalonate derivatives,
  • Aminobenzophenones n-Hexyl 2- (4-diethylamino-2-hydroxybenzoyl) benzoate sold in particular under the trade name Uvinul A+ by
  • the preferred hydrophobic UVA screening agents are butyl methoxydibenzoylmethane and n-hexyl 2- (4- diethylamino-2-hydroxybenzoyl) benzoate . 2) Water-soluble UVA screening agents
  • terephthalylidenedicamphorsulphonic acid manufactured under the name Mexoryl SX by Chimex; - bisbenzoazolyl derivatives as described in patents EP 669 323 and US 2 463 264, and more particularly the compound disodium phenyl dibenzimidazole tetrasulphonate sold under the trade name Neo Heliopan AP by Haarmann and Reimer.
  • the preferred water-soluble UVA screening agent is terephthalylidenedicamphorsulphonic acid.
  • Ethylhexyl dimethyl PABA (Escalol 507 from ISP) ;
  • Ethylhexyl salicylate sold in particular under the name Neo Heliopan OS by Symrise;
  • Neo Heliopan TS sold under the name Neo Heliopan TS by
  • Ethylhexyl methoxycinnamate sold in particular under the trade name Parsol MCX by DSM Nutritional Products,
  • Neo Heliopan E 1000 by Symrise
  • Cinnoxate Glyceryl ethylhexanoate dimethoxycinnamate
  • Octocrylene sold in particular under the trade name Uvinul N539 by BASF;
  • Etocrylene sold in particular under the trade name Uvinul N35 by BASF;
  • Methylbenzylidenecamphor sold in particular under the name Eusolex 6300 by Merck;
  • Ethylhexyl triazone sold in particular under the trade name Uvinul T150 by BASF; Diethylhexyl butamido triazone sold in particular under the trade name Uvasorb HEB by Sigma 3V;
  • Polyorganosiloxanes comprising a benzalmalonate function, such as Polysilicone-15 sold in particular under the trade name Parsol SLX by DSM Nutritional
  • the preferred hydrophobic UVB screening agents are chosen from: Ethylhexyl salicylate
  • UVB screening agents capable of absorbing UV radiation from 280 to 320 nm p-Aminobenzoic acid (PABA) derivatives
  • Glyceryl PABA and PEG-25 PABA sold under the name Uvinul P25 by BASF,
  • Phenylbenzimidazolesulphonic acid sold in particular under the trade name Eusolex 232 by Merck,
  • Camphor benzalkonium methosulphate manufactured under the name Mexoryl SO by Chimex.
  • the preferred water-soluble UVB screening agent is phenylbenzimidazolesulphonic acid.
  • UVA AND UVB SCREENING AGENTS Hydrophobic UVA and UVB screening agents
  • Benzophenone-5 Benzophenone-6 sold in particular under the trade name
  • Drometrizole trisiloxane sold in particular under the name Silatrizole by Rhodia Chimie or manufactured under the name Meroxyl XL by the company Chimex;
  • bis-Resorcinyl triazine derivatives bis (Ethylhexyloxyphenol) methoxyphenyltriazine sold in particular under the trade name Tinosorb S by Ciba Geigy;
  • UVA and UVB screening agents are chosen from:
  • UVA and UVB screening agents Benzophenone derivatives comprising at least one sulphonic radical, for instance:
  • a screening system constituted of: a) at least, as UVA screening agent: butyl methoxydibenzoylmethane, and preferably combined with terephthalylidenedicamphorsulphonic acid, and b) at least, as UVB screening agent, octocrylene, and preferably combined with ethylhexyl salicylate.
  • this screening system will also comprise a hydrophobic UVA and UVB screening agent chosen from drometrizole trisiloxane, bis (ethylhexyloxyphenol) methoxyphenyltriazine, methylenebis (benzotriazolyl) tetramethylbutylphenol in micronised form, or mixtures thereof.
  • a hydrophobic UVA and UVB screening agent chosen from drometrizole trisiloxane, bis (ethylhexyloxyphenol) methoxyphenyltriazine, methylenebis (benzotriazolyl) tetramethylbutylphenol in micronised form, or mixtures thereof.
  • a screening system constituted of: a) at least, as UVA screening agent: n-hexyl 2- (4- diethylamino-2-hydroxybenzoyl) benzoate, and b) at least one hydrophobic UVA and UVB screening agent chosen from drometrizole trisiloxane, bis (ethylhexyloxyphenol) methoxyphenyltriazine, methylenebis (benzotriazolyl) tetramethylbutylphenol in micronised form, or mixtures thereof.
  • a screening system constituted of at least one organic UV screening agent and at least one inorganic UV screening agent .
  • the inorganic UV screening agents used in accordance with the present invention are coated or uncoated metal oxide pigments, for instance pigments of titanium oxide (amorphous or crystallised in rutile and/or anatase form) , of iron oxide, of zinc oxide, of zirconium oxide or of cerium oxide.
  • the inorganic UV screening agents of the invention are particles of metal oxide having a mean elementary particle size of less than or equal to 0.5 ⁇ m, more preferably between 0.05 and 0.5 ⁇ m, and even more preferably between 0.010 and 0.1 ⁇ m, and even more particularly between 0.015 and 0.050 ⁇ m.
  • the pigments may be coated or uncoated.
  • the coated pigments are pigments that have undergone one or more surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53-64, such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminium salts of fatty acids, metal alkoxides (of titanium or of aluminium) , polyethylene, silicones, proteins (collagen, elastin) , alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate .
  • surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53-64 such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium,
  • silicones are organosilicon polymers or oligomers of linear or cyclic, branched or crosslinked structure, of variable molecular weight, obtained by polymerisation and/or polycondensation of suitably functionalised silanes, and are constituted essentially of a repetition of main units in which the silicon atoms are linked together via oxygen atoms (siloxane bond) , optionally substituted hydrocarbon- based radicals being directly attached via a carbon atom to said silicon atoms.
  • silanes also encompasses the silanes required for their preparation, in particular alkyl silanes .
  • the silicones used for coating the pigments that are suitable for the present invention are preferably chosen from the group containing alkyl silanes, polydialkylsiloxanes and polyalkylhydrogenosiloxanes . Even more preferentially, the silicones are chosen from the group containing octyltrimethylsilane, poly- dimethylsiloxanes and polymethylhydrogenosiloxanes .
  • the metal oxide pigments may have been treated with other surface agents, in particular with cerium oxide, alumina, silica, aluminium compounds or silicon compounds, or mixtures thereof.
  • coated pigments are more particularly titanium oxides that have been coated:
  • silica such as the product Sunveil from the company Ikeda
  • silica and iron oxide such as the product Sunveil F from the company Ikeda
  • silica and alumina such as the products Microtitanium Dioxide MT 500 SA and Microtitanium Dioxide MT 100 SA from the company Tayca
  • Tioveil from the company Tioxide and Mirasun TiW 60 from the company Rhodia - with alumina, such as the products Tipaque TTO-55 (B) and Tipaque TTO-55 (A) from the company Ishihara and UVT 14/4 from the company Kemira
  • alumina and aluminium stearate such as the product Microtitanium Dioxide MT 100 T, MT 100 TX, MT 100 Z and MT-Ol from the company Tayca, the products Solaveil CT-10 W and Solaveil CT 100 from the company Uniqema, and the product Eusolex T-AVO from the company Merck,
  • titanium oxide pigments treated with a silicone are preferably Ti ⁇ 2 treated with octyltrimethylsilane and for which the mean size of the elementary particles is between 0.025 and 0.04 m, such as the product sold under the trade name T 805 by the company Degussa Silices, Ti ⁇ 2 treated with a polydimethylsiloxane and for which the mean size of the elementary particles is 21 nm, such as the product sold under the trade name 70250 Cardre UF TiO 2 Si 3 by the company Cardre, anatase/rutile TiO 2 treated with a polydimethylhydrogenosiloxane and for which the mean size of the elementary particles is 25 nm, such as the product sold under the trade name Microtitanium Dioxide USP Grade Hydrophobic by the company Color Techniques.
  • the uncoated titanium oxide pigments are sold, for example, by the company Tayca under the trade names Microtitanium Dioxide MT 500 B or Microtitanium Dioxide
  • the uncoated zinc oxide pigments are, for example:
  • coated zinc oxide pigments are, for example: - those sold under the name Zinc Oxide CS-5 by the company Toshibi (ZnO coated with polymethylhydrogenosiloxane) ;
  • Daitopersion ZN-30 and Daitopersion Zn-50 by the company Daito (dispersions in cyclopolymethylsiloxane/oxyethylenated polydimethyl- siloxane, containing 30% or 50% of nanozinc oxides coated with silica and polymethylhydrogenosiloxane) ;
  • the uncoated cerium oxide pigments are sold, for example, under the name Colloidal Cerium Oxide by the company Rhone Poulenc. Mention may also be made of mixtures of metal oxides, especially of titanium dioxide and of cerium dioxide, including the silica-coated equal-weight mixture of titanium dioxide and of cerium dioxide, sold by the company Ikeda under the name Sunveil A, and also the alumina-, silica- and silicone-coated mixture of titanium dioxide and of zinc dioxide, such as the product M 261 sold by the company Kemira, or the alumina-, silica- and glyercol-coated mixture of titanium dioxide and of zinc oxide, such as the product M 211 sold by the company Kemira.
  • the photoprotective agents are generally present in the compositions of the invention in proportions ranging from 0.01% to 20% by weight, relative to the total weight of the composition, and preferably ranging from 0.1% to 10% by weight, relative to the total weight of the composition.
  • compositions of the invention will be applied to dark skin.
  • dark skin is intended to mean skin of individuals having a high phototype, i.e. skin of individuals having a phototype III to VI, defined according to the Fitzpatrick classification, which is based on the reactivity of the skin to the effects of solar radiation:
  • compositions according to the invention will also comprise at least one desquamating agent.
  • the term "desquamating agent” is intended to mean any compound capable of acting: - either directly on desquamation by promoting exfoliation, such as ⁇ -hydroxy acids (BHAs), in particular salicylic acid and derivatives thereof
  • AHAs ⁇ -hydroxy acids
  • aminosulphonic compounds and in particular 4- (2-hydroxyethyl) piperazine-1-propanesulphonic acid (HEPES) ; 2-oxothiazolidine-4-carboxylic acid (procystein) and derivatives thereof; derivatives of alpha-amino acids of glycine type (as described in EP-O 852 949, and also sodium methyl glycine diacetate sold by BASF under the trade name Trilon M) ; honey; sugar derivatives such as O-octanoyl-6-D-maltose and N-acetylglucosamine .
  • HEP-O 852 949 2-oxothiazolidine-4-carboxylic acid
  • Trilon M sodium methyl glycine diacetate sold by BASF under the trade name Trilon M
  • honey sugar derivatives such as O-octanoyl-6-D-maltose and N-acetylglucosamine .
  • desquamating agents that can be used in the composition according to the invention, mention may be made of: oligofructoses, EDTA and derivatives thereof, laminaria extracts, o-linoleyl-6D-glucose, (3-hydroxy- 2-pentylcyclopentyl) acetic acid, glyceryl trilactate, O-octanyl-6' -D-maltose, S-carboxymethylcysteine, siliceous derivatives of salicylate such as those described in patent EP 0 796 861, oligofucases such as those described in patent EP 0 218 200, 5-acylsalicylic acid salts, active agents with effects on transglutaminase, as in patent EP 0 899 330, extract of the flowers of ficus Opuntia indica, for instance Exfolactive® from Silab, 8-hexadecene-l, 16-dicarboxylic acid, esters of glucose and of
  • beta-hydroxy acids such as 5-n-octanoyl- salicylic acid (or capryloylsalicylic acid) ; urea; glycolic acid, citric acid, lactic acid, tartaric acid, malic acid or mandelic acid; 4- (2-hydroxyethyl) - piperazine-1-propanesulphonic acid (HEPES) ; Saphora japonica extract; honey; N-acetylglucosamine; sodium methyl glycine diacetate, and mixtures thereof.
  • 5-n-octanoyl- salicylic acid or capryloylsalicylic acid
  • urea glycolic acid, citric acid, lactic acid, tartaric acid, malic acid or mandelic acid
  • 4- (2-hydroxyethyl) - piperazine-1-propanesulphonic acid (HEPES) 4- (2-hydroxyethyl) - piperazine-1-propanesulphonic acid (HEPES)
  • Saphora japonica extract honey
  • compositions of the invention of a desquamating agent chosen from 5-n-octanoylsalicylic acid (or capryloylsalicylic acid) of formula below:
  • Mexoryl SAB manufactured by Chimex
  • urea 4- (2-hydroxyethyl) piperazine-1- propanesulphonic acid (HEPES); Saphora japonica extract
  • honey N-acetylglucosamine
  • sodium methyl glycine diacetate and mixtures thereof.
  • the desquamating agent (s) is (are) present in amounts preferably ranging from 0.01% to 2% by weight, relative to the total weight of the composition, and more particularly from 0.05% to 1% by weight, and preferably from 0.05% to 0.5% by weight, relative to the total weight of the composition.
  • the composition of the invention also comprises at least one ingredient that promotes the solubilisation of said derivative and/or at least one ingredient that promotes the stabilisation of the depigmenting agent.
  • ingredients that promote the solubilisation of the depigmenting agent and that can be used in the compositions of the invention mention may in particular be made of:
  • lipophilic derivatives of amino acids that may be used include those of formula
  • n is an integer equal to 0, 1 or 2
  • R' i represents a linear or branched C5-C21 alkyl or alkenyl radical
  • R' 2 represents a hydrogen atom or a C1-C3 alkyl group
  • R' 3 represents a radical chosen from the group formed by a hydrogen atom, a methyl group, an ethyl group and a linear or branched C3 or C4 alkyl radical
  • R' 4 represents a linear or branched C1-C10 alkyl or C2-C10 alkenyl radical, or a sterol residue.
  • a preferred lipophilic amino acid derivative is isopropyl N-lauroylsarcosinate, sold in particular by Ajinomoto under the name Eldew SL 205; ( ⁇ ) fatty alcohols containing from 8 to 26 carbon atoms, such as lauryl alcohol, cetyl alcohol, myristyl alcohol, stearyl alcohol, palmityl alcohol, oleyl alcohol, linoleyl alcohol and 2-octyldodecanol, and mixtures thereof, such as cetearyl alcohol (mixture of cetyl alcohol and of stearyl alcohol) .
  • the 2-octyldodecanol sold under the name Eutanol G by the company Cognis or under the name Isofol 20 N/F by the company Sasol will be used;
  • ethers such as dicaprylyl ether (CTFA name: Dicaprylyl ether) ; or isosorbide ethers such as dimethyl isosorbide; in particular, the dimethyl isosorbide sold under the name Arlasolve DMI by the company Uniqema will be used;
  • esters such as C 12 -C 1 5 fatty alkyl benzoates (Finsolv TN from Finetex) ; or caprylic alcohol esters; in particular, the dicaprylyl carbonate sold under the name Cetiol CC by the company Cognis will be used;
  • isononanoate derivatives such as ethylhexyl isononanoate, for instance 2-ethylhexyl isononanoate or ethyl-2-hexyl isononanoate or octyl isononanoate, in particular Dragoxat 89 from the company Dragocco or Dermol 89.
  • the expression "ingredient that promotes the stabilisation of the depigmenting agents” is intended to mean in particular an ingredient that makes it possible either (i) to stabilise said depigmenting agent or (ii) to stabilise the cosmetically acceptable medium in which said depigmenting agent is present.
  • the ingredient that promotes the stabilisation of said depigmenting agents may in particular be present in a particular galenical form that contributes towards the stabilisation of said depigmenting agent in said cosmetically acceptable medium.
  • ingredients for stabilising said depigmenting agents that can be used in the compositions of the invention, mention may in particular be made of: a) block polymers and/or copolymers; b) amphiphilic lipids of ionic or nonionic type present in the form of vesicles in dispersion; c) constituent polymers of microspheres or of microcapsules; d) constituent polymers of microparticles; e) polymers and/or surfactants forming microemulsions; f) polymers in the form of thin films; g) polyolefin emulsifiers with a polar portion, the composition being in the form of a water-in-oil emulsion; h) amphiphilic polymers comprising 2-acrylamido-2- methylpropanesulphonic acid (AMPS) units.
  • AMPS 2-acrylamido-2- methylpropanesulphonic acid
  • block polymers and/or copolymers It is known practice to encapsulate lipophilic active agents in micelles of block copolymers, for example poly (ethylene oxide-propylene oxide) diblock or triblock copolymers.
  • a block amphiphilic copolymer comprising at least one nonionic hydrophilic polymeric block and at least one particular hydrophobic polymeric block will be used in the composition of the invention.
  • the molecular weight of the block copolymer is generally between 1000 and 100 000.
  • the weight ratio of the ionic or nonionic hydrophilic polymeric block (s) to the hydrophobic polymeric block (s) is between 1/100 and 50/1.
  • the hydrophobic polymeric block is in particular chosen from:
  • - R is chosen from H and -CH 3 ,
  • - X is chosen from alkyl oxides of -OR' type in which R' is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms .
  • the hydrophobic polymeric block is obtained from one or more hydrophobic monomers chosen from methyl methacrylate, ethyl methacrylate, n-butyl
  • the hydrophobic polymeric block is chosen from polystyrene, poly (tert-butylstyrene) , polymethyl methacrylate, polyethyl acrylate, polybutyl methacrylate and poly(C3-C6 alkylene oxide) s.
  • the nonionic hydrophilic polymeric block is chosen from polyethylene oxides.
  • the block copolymer is chosen from the following block copolymers:
  • amphiphilic lipids of ionic or nonionic type the depigmenting agent (s) is (are) combined with ionic or nonionic amphiphilic lipids present in the form of vesicles of ionic type (e.g.: liposomes) and/or nonionic type (e.g.: niosomes) as a dispersion in the physiologically acceptable medium of the composition, in particular as an aqueous dispersion.
  • ionic or nonionic amphiphilic lipids present in the form of vesicles of ionic type (e.g.: liposomes) and/or nonionic type (e.g.: niosomes) as a dispersion in the physiologically acceptable medium of the composition, in particular as an aqueous dispersion.
  • These lipid vesicles contributes towards stabilising said depigmenting agents in the physiologically acceptable medium of the composition.
  • These lipid vesicles may have an aqueous core or an oily core.
  • Lipid vesicles with an oily core will preferably be used.
  • the term "vesicle” is intended to mean any particulate structure comprising, on the one hand, a membrane or "lipid phase” constituted of one or more concentric leaflets, these leaflets comprising one or more bimolecular layers based on ionic or nonionic amphiphilic lipids, and, on the other hand, an aqueous or oily phase encapsulated by this lipid phase.
  • lipid phase constituted of one or more concentric leaflets, these leaflets comprising one or more bimolecular layers based on ionic or nonionic amphiphilic lipids, and, on the other hand, an aqueous or oily phase encapsulated by this lipid phase.
  • liposomes and niosomes in particular constitute such vesicles .
  • Niosomes are vesicles prepared from nonionic amphiphilic lipids. Reference may in particular be made to the description of patent FR 8 907 947.
  • nonionic amphiphilic lipids mention may in particular be made of optionally oxyethylenated alkyl- or polyalkyl esters of a polyol, and optionally oxyethylenated polyol ethers, having a melting point of at least 40 0 C.
  • Liposomes are vesicles prepared from ionic amphiphilic lipids. These vesicles are particles formed from a membrane constituted of one or more concentric leaflets, these leaflets comprising one or more biomolecular layers of amphiphilic lipids encapsulating an aqueous or oily phase.
  • the aqueous phase may contain water-soluble active substances and the biomolecular layers of amphiphilic lipids may contain lipophilic active substances.
  • These vesicles generally have a mean diameter of between 0.01 and 5 micrometres.
  • the ionic amphiphilic lipids may be anionic amphiphilic lipids or cationic amphiphilic lipids.
  • anionic amphiphilic lipids mention may in particular be made of:
  • - neutralised anionic lipids preferably chosen from alkali metal salts of dicetyl phosphate, and of dimyristyl phosphate, in particular the sodium and potassium salts, alkali metal salts of phosphatidic acid, in particular the sodium salt, alkali metal salts of cholesteryl sulphate, in particular the sodium salt, alkali metal salts of cholesteryl phosphate, in particular the sodium salt, and salts of lipoamino acids such as monosodium and disodium acylglutamates, more particularly the disodium salt of N-stearoyl-L- glutamic acid sold under the name Acylglutamate HS21 by the company Ajinomoto, - amphoteric lipids, in particular pure soyabean phosphatidyIethanolamine, - alkylsulphonic derivatives.
  • alkali metal salts of dicetyl phosphate, and of dimyristyl phosphate in particular the sodium and potassium salt
  • cationic amphiphilic lipids use may in particular be made of quaternary ammonium salts and fatty amines and salts thereof.
  • double- liposome compositions for the simultaneous treatment of the surface and deep layers of the skin, comprising a first dispersion of lipid vesicles that are capable of penetrating into the deep layers of the skin and that contain at least one active agent capable of treating these deep layers, and a second dispersion of lipid vesicles that are capable of penetrating into the surface layers of the skin and that contain at least one active agent capable of treating these surface layers.
  • the depigmenting agents will preferably be present in the second dispersion of lipid vesicles that are capable of penetrating into the surface layers of the skin .
  • active agents targeting the dermis e.g.: anti-ageing active agents
  • active agents targeting the dermis e.g.: anti-ageing active agents
  • Oleosomes are oily globules provided with a lamellar liquid crystal coating, dispersed in an aqueous phase, with a mean diameter of generally less than 500 nanometres.
  • said active agents may be combined with particles of small sizes .
  • They may be solid particles constituted of the combination of said hydroxylated diphenylmethane derivative of formula (I) or (II) and of at least one polymer .
  • This polymer contributes towards stabilising said hydroxylated diphenylmethane derivative of formula (I) or (II) in the physiologically acceptable medium of the composition.
  • particles of small size mainly encompass two different systems: “spherical particles” constituted of a polymer matrix in which said depigmenting agent is absorbed and/or adsorbed and/or mixed, and also “microcapsules” having a structure of core-shell type, i.e. a structure constituted of a lipid core that is liquid at ambient temperature, containing the depigmenting agent in solubilised form, said core being encapsulated in a continuous protective shell that is insoluble in the medium.
  • spherical particles constituted of a polymer matrix in which said depigmenting agent is absorbed and/or adsorbed and/or mixed
  • microcapsules having a structure of core-shell type, i.e. a structure constituted of a lipid core that is liquid at ambient temperature, containing the depigmenting agent in solubilised form, said core being encapsulated in a continuous protective shell that is insoluble in the medium.
  • Microcapsules will preferably be used.
  • the spherical particles generally have a mean size of between 0.05 and 0.5 ⁇ m.
  • microcapsules are generally of small size so as to obtain optimum bioavailability of the depigmenting agents.
  • the size of these microcapsules is between 0.01 and 1 ⁇ m, and more particularly between 0.030 and 0.5 ⁇ m.
  • microcapsules As described in patent application EP-O 274 961, the microcapsules provided with a lamellar coating, described in patent application EP-O 780 115, the nanocapsules of which the water-insoluble continuous polymer shell is constituted of polyesters, as described in applications EP 1 025 901, FR-2 787 730 and EP-I 034 839, or alternatively the biodegradable microcapsules described in patent application FR-2 659 554, or the nonbiodegradable microcapsules described in patent application WO 93/05753.
  • microcapsules made of biodegradable polymers penetrate the skin and degrade in the epidermis under the action of the enzymes present therein, whereas the microcapsules made of non-biodegradable polymers only penetrate the surface layers of the stratum corneum and are eliminated naturally during skin renewal.
  • constituent polymers of microcapsules that can be used in the compositions of the invention in combination with the hydroxylated diphenylmethane derivatives of formula (I) or (II), mention may in particular be made of poly-L- and DL-lactides and polycaprolactones, polyglycolides and copolymers thereof, polymers derived from the polymerisation of an alkyl cyanoacrylate (the alkyl chain containing from 2 to 6 carbon atoms) ; synthetic or natural water- dispersible anionic polymers; polyesters of the poly (alkylene adipate) type; dendritic polymers; copolymers of vinyl chloride and of vinyl acetate, copolymers of methacrylic acid and of methacrylic acid methyl ester, polyvinyl acetophthalate, cellulose acetophthalate, copolymers of polyvinylpyrrolidone- crosslinked vinyl acetate, polyethylene vinyl acetates, polyacrylonitriles, polyacrylamides
  • the depigmenting agents will be combined with constituent polymers of microparticles .
  • These polymers contribute towards stabilising said depigmenting agent in the cosmetically acceptable medium of the composition.
  • microparticles especially encompasses “porous particles”, and in particular "microspheres”.
  • porous particles denotes particles with a structure comprising pores. This pore structure may at least partly enable the incorporation of one or more active agents into said particles.
  • the structure of the particles may be of matrix type like a sponge. It may also be of vesicular type, i.e. the particle has an inner cavity delimited by a porous wall.
  • the porosity associated with the size of the particles is characterized quantitatively by their specific surface area. Porous particles with a specific surface area, measured according to the BET method, of greater than or equal to 1 m 2 /g will in particular be used.
  • the specific surface area measured according to the BET method corresponds to the total specific surface area, i.e. it includes the surface formed by the pores.
  • the particles of the invention have a specific surface area measured by BET ranging in particular from 2.5 to 100 m 2 /g.
  • the porous particles that can be used in the compositions of the invention are generally individualised particles.
  • the expression "individualised particles” denotes particles which are not grouped together in the form of an aggregate or of an agglomerate. These particles in particular have a density of greater than or equal to 0.15 g/cm 3 , and especially ranging from 0.2 to 5 g/cm 3 . These particles preferably have a volume-average diameter of less than or equal to 10 ⁇ m. This is because such particles can penetrate into the sebaceous follicle by application of a mechanical force. This mechanical force generally comes from massaging, which, besides the pushing that it exerts, generates a pump effect in the follicle.
  • the particles gradually reach the follicular canal, in which they are capable of absorbing sebum and, where appropriate, releasing the active compound that they bear.
  • the constituent material of the particles is then discarded through the flow of sebum and/or the growth of the hair, thus making it possible to avoid any possible adverse reaction by the body with respect to this material.
  • Porous particles which are in particular spherical, bearing a number-average size that may range from 0.1 to 50 ⁇ m, especially from 0.1 to 20 ⁇ m, and most particularly from 0.5 to 10 ⁇ m, will in particular be used.
  • Polyamide particles in particular made of Nylon 6, Nylon 6-6, Nylon 12 or Nylon 6-12, such as those sold by the company Atofina under the generic name Orgasol, may be used as preferred porous particles.
  • This encapsulation system that allows follicular targeting is particularly advantageous in compositions for use in the treatment of oily skin.
  • said depigmenting agents are combined, in the composition, with particular polymers and/or surfactants, the composition being in the form of a microemulsion .
  • These polymers and/or surfactants contribute towards stabilising said hydroxylated diphenylmethane derivative of formula (I) or (II) in the physiologically acceptable medium of the composition.
  • Microemulsions are generally oil-in-water emulsions of which the oil globules have a very fine particle size, i.e. a number-average size of less than 0.1 ⁇ m .
  • microemulsions may be stabilised with a lamellar liquid crystal coating obtained by combining a hydrophilic surfactant and a lipophilic surfactant.
  • the particular polymers allowing the preparation of microemulsions may be chosen from:
  • the particular surfactants allowing the preparation of nanoemulsions may in particular be a ternary system of surfactants, including a mixture of nonionic surfactants and an ionic surfactant, as described in patent EP 1 353 629, incorporated herein by way of reference.
  • the hydrophobic-chain anionic polymer comprises hydrophobic chains chosen from linear or branched, saturated or unsaturated hydrocarbon-based chains containing from 6 to 30 carbon atoms, cycloaliphatic divalent groups and aromatic divalent groups, and preferably chosen from alkyl, arylalkyl, alkylaryl, alkylene, methylenedicyclohexyl, isophorone and phenylene chains .
  • the anionic polymer is in particular chosen from acrylic acid or methacrylic acid copolymers, 2- acrylamido-2-methylpropanesulphonic acid copolymers, and mixtures thereof.
  • the anionic polymer is obtained by copolymerisation of a monomer (a) chosen from ⁇ , ⁇ -ethylenically unsaturated carboxylic acids (monomer a' ) and 2-acrylamido-2-methylpropanesulphonic acid (monomer a' ' ) , with a non-surfactant ethylenically unsaturated monomer (b) different from (a) and/or an ethylenically unsaturated monomer (c) derived from the reaction of an ⁇ , ⁇ -monoethylenically unsaturated acrylic monomer or of a monoethylenically unsaturated isocyanate monomer with a monohydric nonionic amphiphilic component or with a primary or secondary fatty amine.
  • a monomer (a) chosen from ⁇ , ⁇ -ethylenically unsaturated carboxylic acids (monomer a' ) and 2-acrylamido-2-methylpropanesulphonic acid (
  • the anionic polymer is an acrylic terpolymer obtained from (a) an ⁇ , ⁇ -ethylenically unsaturated carboxylic acid, (b) a non-surfactant ethylenically unsaturated monomer different from (a) , and (c) a nonionic urethane monomer which is the product of reaction of a monohydric nonionic amphiphilic compound with a monoethylenically unsaturated isocyanate.
  • the anionic polymer is chosen from acrylic acid/ethyl acrylate/alkyl acrylate terpolymer, acrylates/steareth-20 methacrylate copolymer, (meth) acrylic acid/ethyl acrylate/oxyethylenated
  • the water-soluble nonionic polymer may be chosen from ethylene oxide homopolymers and copolymers; polyvinyl alcohols; vinylpyrrolidone homopolymers and copolymers; vinylcaprolactam homopolymers and copolymers; polyvinyl methyl ether homopolymers and copolymers; neutral acrylic homopolymers and copolymers; Ci-C2-alkyl-celluloses and derivatives thereof; Ci-C3-alkyl-guars or C1-C3- hydroxyalkyl-guars .
  • the ternary surfactant system may in particular comprise : (a) a mixture of at least two nonionic surfactants comprising at least one ethoxylated fatty ester comprising 8 to 100 (in particular 10 to 80, and better still 40) ethylene oxide units and at least one fatty acid ester of sorbitan; and
  • At least one ionic surfactant chosen from alkali metal salts of cetyl phosphate and alkali metal salts of palmitoyl sarcosinate.
  • the ethoxylated fatty ester is preferably polyethylene glycol 40 EO stearate and the fatty acid ester of sorbitan is preferably sorbitan tristearate.
  • the ionic surfactant is in particular chosen from potassium cetyl phosphate and sodium palmitoyl sarcosinate, and mixtures thereof.
  • said hydroxylated diphenylmethane derivatives of formula (I) or (II) are combined with at least one water-soluble or water-dispersible polymer in the form of a thin film.
  • composition is therefore in the form of a thin film.
  • This water-soluble or water-dispersible polymer contributes towards stabilising said depigmenting agent in the physiologically acceptable medium of the composition .
  • the term "film” is intended to mean a thin, manipulable solid.
  • the term “thin” is intended to refer to a solid having a maximum thickness of 1000 ⁇ m.
  • This film is generally of a suitable size so that it can be readily manipulated by the user. It may be square, rectangular or disc-shaped, or may have any other shape.
  • Each film generally has a thickness of from 10 ⁇ m to 1000 ⁇ m, preferably from 20 to 500 ⁇ m, and better still from 50 to 300 ⁇ m. It may have a surface area of from 0.25 to 25 cm 2 , and preferably from 2 to 10 cm 2 .
  • These thin films generally contain less than 10% by weight of water, preferably less than 5% by weight, relative to the total weight of the film, and more preferably do not contain water.
  • the thin film comprises a water-soluble or water- dispersible polymer that may be chosen from:
  • polymers of protein type such as wheat or soyabean proteins; keratin, for example keratin hydrolysates and sulphonic keratins; casein; albumin; collagen; glutelin; glucagon; gluten; zein; gelatins and derivatives thereof; (2) polymers derived from chitin or from chitosan, such as anionic, cationic, amphoteric or nonionic chitin or chitosan polymers; (3) polysaccharide polymers such as, in particular, (i) cellulosic polymers, for instance hydroxyethyl- cellulose, hydroxypropylcellulose, hydroxypropylmethyl- cellulose, methylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose and quaternised cellulose derivatives; and (ii) starches and derivatives thereof;
  • acrylic polymers or copolymers such as polyacrylates, polymethacrylates and copolymers thereof; (5) vinyl polymers such as polyvinylpyrrolidones, copolymers of methyl vinyl ether and of maleic anhydride, the copolymer of vinyl acetate and of crotonic acid, copolymers of vinylpyrrolidone and of vinyl acetate, copolymers of vinylpyrrolidone and of caprolactam, polyvinyl alcohols; (6) polymers of natural origin, which are optionally modified, such as gum Arabic, guar gum, xanthan derivatives, karaya gum; alginates, carraghenans, ulvanes and other algal colloids; glycoaminoglycans, hyaluronic acid and its derivatives; shellac, sandarac gum, dammar resins, elemi gums, copal resins; deoxyribonucleic acid; mucopolysaccharides, such as hyl
  • water-soluble polymers mention may also be made of caprolactams, pullulan, pectin, mannan and galactomannans, glucomannans and derivatives thereof.
  • the water-soluble polymer may be a cellulosic polymer, in particular hydroxypropyl- cellulose or hydroxypropylmethylcellulose, or else an alginate, in particular sodium alginate.
  • emulsifiers mention may in particular be made of:
  • - amphiphilic polymers comprising 2-acrylamido-2- methylpropanesulphonic acid (AMPS) units, in an oil-in- water emulsion.
  • AMPS 2-acrylamido-2- methylpropanesulphonic acid
  • the polyolefins with a polar portion contribute towards stabilising said depigmenting agent in the physiologically acceptable medium of the composition.
  • the polyolefins with polar portion (s) used in the composition of the invention are generally constituted of a polyolefinic apolar portion and of at least one polar portion.
  • the polyolefinic apolar portion comprises at least 40 carbon atoms, and preferably from 60 to 700 carbon atoms.
  • This apolar portion may be chosen from polyolefins such as oligomers, polymers and/or copolymers of ethylene, propylene, 1-butene, isobutene, 1-pentene, 2-methyl-l-butene, 3-methyl-l- butene, 1-hexene, 1-heptene, 1-octene, 1-decene, 1-undecene, 1-dodecene, 1-tridecene, 1-tetradecene, 1-pentadecene, 1-hexadecene, 1-heptadecene and 1-octadecene .
  • polyolefins are hydrogenated or non-hydrogenated.
  • the polar portion of the polyolefins with a polar portion may be anionic, cationic, nonionic, zwitterionic or amphoteric. It is, for example, constituted of polyalkylene (in particular polyoxyethylene) glycols or polyalkyleneimines, or alternatively of carboxylic or dicarboxylic acids, or anhydrides thereof or derivatives thereof such as esters thereof, amides thereof and salts thereof, and mixtures thereof.
  • the polyolefins with a carboxylic acid polar portion may be derived, for example, from the reaction between a polyolefin and at least one carboxylic acid or anhydride that is optionally totally or partially salified, chosen from the group comprising succinic acid or anhydride, maleic acid, maleic anhydride, fumaric acid, itaconic acid, citraconic acid
  • the polar portion of the polyolefin is chosen from the group comprising polyoxyethylene, succinic acid or anhydride, esters or amides of succinic acid or anhydride, alkali metal or alkaline- earth metal or organic salts of succinic acid or anhydride, or partial salts of succinic acid or anhydride monoesters or monoamides.
  • polyolefins with a polar portion that are preferred in the compositions of the invention are polyolefins with an optionally modified succinic end group, as described in patent EP 1 172 089, incorporated herein by way of reference.
  • polystyrene resins with a succinic end group mention may in particular be made of polyisobutylenes with an optionally modified, esterified succinic end group, in particular esterified with diethanolamine, and salts thereof, in particular the diethanolamine salts, such as the products sold under the names Lubrizol ® 2724, Lubrizol ® 2722 and Lubrizol ® 5603 by the company Lubrizol .
  • Another polyolefin with a polar portion that is particularly preferred is an ester of poly (diethanolaminoethyl isobutenyl succinate) and of triethanolamine . This product is sold, for example, under the name Chemcinnate ® 2000 by the company Chemron.
  • polystyrene foam As a polyolefin with a polar portion, use may also be made of a poly (glyceryl isobutenyl succinate) ester, in particular the product sold under the name Chemcinnate ® 1000 AF by the company Chemron. h) amphiphilic polymers comprising AMPS units
  • the composition according to the invention is in the form of an oil-in-water emulsion and comprises at least one hydroxylated diphenylmethane derivative of formula (I) or (II) and at least one amphiphilic polymer comprising 2-acrylamido-2-methylpropanesulphonic acid (AMPS) units.
  • AMPS 2-acrylamido-2-methylpropanesulphonic acid
  • This amphiphilic polymer comprising 2-acrylamido- 2-methylpropanesulphonic acid (AMPS) units contributes towards stabilising said hydroxylated diphenylmethane derivative of formula (I) or (II) in the physiologically acceptable medium of the composition.
  • AMPS 2-acrylamido- 2-methylpropanesulphonic acid
  • amphiphilic polymer comprising 2-acrylamido- 2-methylpropanesulphonic acid (AMPS) units that can be used in the compositions of the invention, mention may be made of those described in patent application EP 1 466 587.
  • AMPS 2-acrylamido- 2-methylpropanesulphonic acid
  • amphiphilic polymers mention may be made of copolymers of AMPS and of oxyethylenated C12-C14 alkyl methacrylate, comprising in particular from 7 to 23 oxyethylenated groups.
  • ingredients that promote the solubilisation and/or ingredients that promote the stabilisation of said depigmenting agent according to the invention will be present in the composition in a content generally ranging from 0.01% to 30% by weight, relative to the total weight of the composition, preferably from 0.05% to 15% by weight, more preferably from 0.1% to 10% by weight, and more particularly from 0.1% to 5% by weight, relative to the total weight of the composition .
  • compositions according to the invention as defined above may be in any of the galenical forms conventionally used for topical application, and in particular in the form of aqueous or aqueous-alcoholic solutions, of oil-in-water (O/W) or water-in-oil (W/O) or multiple (triple: W/O/W or 0/W/O) emulsions, of aqueous gels, or of dispersions of a fatty phase in an aqueous phase by means of polymeric microparticles such as microspheres and microcapsules, or of lipid vesicles of ionic and/or nonionic type (liposomes, niosomes, oleosomes), of microemulsions or of thin films.
  • aqueous or aqueous-alcoholic solutions of oil-in-water (O/W) or water-in-oil (W/O) or multiple (triple: W/O/W or 0/W/O) emulsions,
  • compositions are prepared according to the usual methods .
  • compositions used according to the invention may be more or less fluid and may have the appearance of a white or coloured cream, an ointment, a milk, a lotion, a serum, a paste or a foam. They may be optionally applied to the skin in the form of an aerosol. They may also be in solid form, and for example in the form of a stick.
  • composition used according to the invention comprises an oily phase
  • said phase preferably contains at least one oil. It may also contain other fatty substances.
  • oils that can be used in the composition of the invention, mention may, for example, be made of:
  • oils of plant origin such as liquid triglycerides of fatty acids comprising from 4 to 10 carbon atoms, for instance heptanoic or octanoic acid triglyerides or alternatively, for example, sunflower oil, maize oil, soyabean oil, marrow oil, grapeseed oil, sesame oil, hazelnut oil, apricot oil, macadamia oil, arara oil, castor oil, avocado oil, caprylic/capric acid triglycerides such as those sold by the company Stearineries Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba oil, shea butter oil;
  • liquid triglycerides of fatty acids comprising from 4 to 10 carbon atoms for instance heptanoic or octanoic acid triglyerides or alternatively, for example, sunflower oil, maize oil, soyabean oil, marrow oil, grape
  • esters and ethers in particular of fatty acids, for instance oils of formulae R1COOR2 and R1OR2 in which Ri represents the residue of a fatty acid comprising from 8 to 29 carbon atoms, and R2 represents a branched or unbranched hydrocarbon-based chain containing from 3 to 30 carbon atoms, such as, for example, purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates and decan
  • silicone oils for instance volatile or non-volatile polymethylsiloxanes (PDMSs) containing a linear or cyclic silicone chain, which are liquid or pasty at ambient temperature, in particular cyclopolydimethyl- siloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups that are pendant or at the end of the silicone chain, said groups containing from 2 to 24 carbon atoms; phenyl silicones, for instance phenyl trimethicones, phenyl dimethicones, phenyltrimethyl- siloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes, 2-phenylethyl- trimethylsiloxysilicates and polymethylphenylsiloxanes; - and mixtures thereof.
  • PDMSs volatile or non-volatile
  • hydrocarbon-based oil in the list of oils mentioned above is intended to mean any oil comprising predominantly carbon and hydrogen atoms, and optionally ester, ether, fluoro, carboxylic acid and/or alcohol groups.
  • the other fatty substances that may be present in the oily phase are, for example, fatty acids containing from 8 to 30 carbon atoms, for instance stearic acid, lauric acid, palmitic acid and oleic acid; waxes, for instance lanolin, beeswax, carnauba wax or candelilla wax, paraffin waxes, lignite waxes or microcrystalline waxes, ceresine or ozokerite, synthetic waxes such as polyethylene waxes, Fischer-Tropsch waxes; silicone resins such as trifluoromethyl (C1-C4) alkyl dimethicone and trifluoropropyl dimethicone; and silicone elastomers, such as the products sold under the name KSG by the company Shin-Etsu, under the names Trefil, BY29 or EPSX by the company Dow Corning or under the name Gransil by the company Grant Industries.
  • fatty acids containing from 8 to 30 carbon atoms for instance stearic
  • fatty substances may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example of consistency and of texture.
  • the composition according to the invention is a water-in-oil (W/O) or oil-in-water (O/W) emulsion.
  • the proportion of the oily phase of the emulsion may range from 5% to 80% by weight, and preferably from 5% to 50% by weight, relative to the total weight of the composition .
  • the emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture, and optionally a coemulsifier .
  • the emulsifiers are suitably chosen according to the emulsion to be obtained (W/O or O/W) .
  • the emulsifier and the coemulsifier are generally present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% by weight, relative to the total weight of the composition.
  • dimethicone copolyols such as the mixture of cyclomethicone and dimethicone copolyol, sold under the name DC 5225 C by the company Dow Corning
  • alkyl dimethicone copolyols such as the lauryl methicone copolyol sold under the name Dow Corning 5200 Formulation Aid by the company Dow Corning and the cetyl dimethicone copolyol sold under the name Abil EM 9OR by the company Goldschmidt.
  • a surfactant for W/O emulsions use may also be made of a crosslinked elastomeric solid organopolysiloxane comprising at least one oxyalkylenated group, such as those obtained according to the procedure of Examples 3, 4 and 8 of document US-A-5 412 004 and of the examples of document US-A-5 811 487, and in particular the product of Example 3 (synthesis example) of patent US-A-5 412 004, and such as the product sold under the reference KSG 21 by the company Shin Etsu.
  • emulsifiers of nonionic emulsifiers such as oxyalkylenated (more particularly polyoxy- ethylenated) fatty acid esters of glycerol; oxyalkylenated fatty acid esters of sorbitan; oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty acid esters; oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alcohol ethers; sugar esters such as sucrose stearate; and mixtures thereof such as the mixture of glyceryl stearate and PEG-40 stearate .
  • nonionic emulsifiers such as oxyalkylenated (more particularly polyoxy- ethylenated) fatty acid esters of glycerol; oxyalkylenated fatty acid esters of sorbitan; oxyalkylenated (oxyethylenated and
  • the cosmetic or dermatological composition of the invention may also contain adjuvants that are customary in the cosmetics or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, fragrances, fillers, bactericides, odour absorbers, dyestuffs, plant extracts, salts, antioxidants, basic agents, acids or nonionic, anionic or cationic surfactants.
  • adjuvants that are customary in the cosmetics or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, fragrances, fillers, bactericides, odour absorbers, dyestuffs, plant extracts, salts, antioxidants, basic agents, acids or nonionic, anionic or cationic surfactants.
  • these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01% to 20% of the total weight of the composition. Depending on their nature, these adjuvants may be introduced into the fatty phase, into the aqueous phase and/or into lipid vesicles.
  • hydrophilic or lipophilic gelling agents mention may in particular be made of carbopols, luvigels, hostacerin AMPS, Simulgel products, Sepigel products, xanthan gum, guar gum, cellulose gum, alginates, and mixtures thereof. Mention may also be made of hectorites.
  • compositions according to the invention may be applied directly to the skin or, alternatively, to cosmetic or dermatological supports of the occlusive or non-occlusive type, intended to be applied locally to the skin.
  • the support may be an "occlusive" support.
  • the support is constituted of a thermoplastic material chosen from high-density and low-density polyethylenes, polypropylenes, polyvinyl chlorides, ethylene/vinyl acetate copolymers, polyesters and polyurethanes, or of a complex of such materials. These materials may also be present in stratified form with at least one metal foil such as an aluminium foil.
  • the support layer may be of any suitable thickness that affords the desired support and protective functions.
  • the thickness of the support layer is between approximately 20 ⁇ m and approximately 1.5 mm.
  • the support layer is sufficiently flexible so as to be able to follow the profile of the skin perfectly, and so as not to cause the user any sensation of discomfort.
  • the support is "non- occlusive".
  • a support constituted of a paper, a porous or perforated thermoplastic material, a fabric, a nonwoven or a perforated nonwoven is advantageously used.
  • compositions according to the invention may be combined with orally administered compositions containing additional cosmetic active agents that have a beneficial effect on the appearance of the skin, such as, for example, additional active agents intended to combat the signs of skin ageing or additional active agents intended to combat oily skin.
  • the additional ingredient used in the composition of the invention may also be a cosmetic or pharmaceutical ingredient and/or active agent, in particular ingredients and/or active agents that are beneficial to the appearance and/or the texture of the skin .
  • compositions of the invention may comprise at least one filler.
  • fillers should be understood to mean colourless or white, mineral or synthetic particles of any form, which are insoluble in the medium of the composition irrespective of the temperature at which the composition is produced. These fillers serve in particular to modify the rheology or the texture of the composition.
  • the fillers may be mineral or organic and of any form, platelet-shaped, spherical or oblong, irrespective of the crystallographic form (for example lamellar, cubic, hexagonal, orthorhombic, etc.) . Mention may be made of talc, mica, silica, kaolin, polyamide (Nylon ® ) powder (Orgasol ® from Atochem) , poly- ⁇ -alanine powder and polyethylene powder, tetrafluoroethylene polymer (Teflon ® ) powder, lauroyllysine, starch, boron nitride, hollow polymer microspheres such as polyvinylidene chloride/- acrylonitrile microspheres, for instance Expancel ®
  • compositions according to the invention may in particular comprise at least one matting filler, a soft-focus filler, a fluorescer, an abrasive or exfoliant filler, and mixtures thereof.
  • the term "matting filler” denotes a spherical or non-spherical, porous or non-porous particle with a refractive index of less than or equal to 2.2, especially less than or equal to 2 and in particular less than or equal to 1.8, preferably ranging from 1.3 to 1.6.
  • the "matting fillers” according to the invention have a volume size comparable to that of the pearlescent agents used. The preferred size of the fillers is thus less than 15 ⁇ m measured with a laser granulometer, for instance the Mastersizer 2000 ® from Malvern or the BI90+ from Brookhaven Instruments Corporation.
  • the "matting fillers" are spherical. In another preferential embodiment of the invention, the "matting fillers” are porous. In this case, the specific surface area of the particles, which may be related to the porosity, is greater than 10 m 2 /g and preferably greater than 50 m 2 /g. Mattness test:
  • the matting nature of the fillers according to the invention is defined by means of a gonioreflectometer measurement. To do this, the composition containing 5% fillers is spread onto a contrast card (Pruf recognition type 24/5 - 250 cm 2 sold by the company Erichsen) using a mechanical film spreader (wet thickness of 30 ⁇ m) . The composition is then dried overnight at a temperature of 37°C, and the reflection is then measured using a gonioreflectometer . The result obtained is the ratio R between the specular reflection and the diffuse reflection. The value of R is proportionately smaller the greater the matting effect.
  • the matting fillers according to the invention are those which, at a content of 5% in a cosmetic composition, give a value of R of less than 1 and preferably less than 0.75.
  • the matting effect of the agent and/or composition containing it may especially be evaluated using a gonioreflectometer, by measuring the ratio R between the specular reflection and the scattered reflection.
  • a value of R of less than or equal to 2 generally reflects a matting effect.
  • the matting filler may especially be chosen from a rice starch or a corn starch, kaolinite, talc, a pumpkin seed extract, cellulose microbeads, plant fibres, synthetic fibres, in particular polyamide fibres, expanded acrylic copolymer microspheres, polyamide powders, silica powders, polytetrafluoro- ethylene powders, silicone resin powders, acrylic polymer powders, wax powders, polyethylene powders, powders of elastomeric crosslinked organopolysiloxane coated with silicone resin, talc/titanium dioxide/alumina/silica composite powders, amorphous mixed silicate powders, silicate particles and especially mixed silicate particles, and mixtures thereof .
  • the matting agent may especially be chosen from a rice starch or a corn starch, kaolinite, talc, a pumpkin seed extract, cellulose microbeads, plant fibres, synthetic fibres, in particular polyamide fibres, expanded acrylic copolymer microspheres, polyamide powders, silica powders, polytetrafluoro- ethylene powders, silicone resin powders, acrylic polymer powders, wax powders, polyethylene powders, powders of elastomeric crosslinked organopolysiloxane coated with silicone resin, talc/titanium dioxide/- alumina/silica composite powders, amorphous mixed silicate powders, silicate particles and especially mixed silicate particles, and mixtures thereof.
  • matting agents examples include:
  • fibres such as silk fibre, cotton fibre, wool fibre, flax fibre, cellulose fibre extracted especially from wood, from vegetables or from algae, polyamide fibre
  • nylon ® modified cellulose fibre, poly-p- phenyleneterephthamide fibre, acrylic fibre, polyolefin fibre, glass fibre, silica fibre, aramid fibre, carbon fibre, Teflon ® fibre, insoluble collagen fibre, polyester fibre, polyvinyl chloride or polyvinylidene chloride fibre, polyvinyl alcohol fibre, polyacrylonitrile fibre, chitosan fibre, polyurethane fibre, polyethylene phthalate fibre, fibres formed from a mixture of polymers, resorbable synthetic fibres, and mixtures thereof described in patent application EP 1 151 742; - expanded acrylic copolymer microspheres such as those sold by the company EXPANCEL under the name Expancel 551 ® ;
  • Nylon ® polyamide powders
  • Nylon 12 particles of the Orgasol type from Arkema with a mean size of 10 microns and a refractive index of 1.54
  • silica powders for instance Silica beads SB150 from Miyoshi with a mean size of 5 microns and a refractive index of 1.45,
  • - polytetrafluoroethylene powders for instance PTFE Ceridust 9205F from Clariant, with a mean size of 8 microns and a refractive index of 1.36
  • silicone resin powders for instance the silicone resin Tospearl 145A from GE Silicone with a mean size of 4.5 microns and a refractive index of 1.41
  • acrylic copolymer powders especially of polymethylmethacrylate, for instance the PMMA particles Jurymer MBI from Nihon Junyoki, with a mean size of 8 microns and a refractive index of 1.49, or the Micropearl M100 ® and F 80 ED ® particles from the company Matsumoto Yushi- Seiyaku,
  • polyethylene powders especially comprising at least one ethylene/acrylic acid copolymer, and in particular constituted of ethylene/acrylic acid copolymers, for instance the particles Flobeads EA 209 from Sumitomo (with a mean size of 10 microns and a refractive index of 1.48) ,
  • elastomeric crosslinked organopolysiloxane powders coated with silicone resin especially with silsesquioxane resin, as described, for example, in patent US 5 538 793.
  • Such elastomeric powders are sold under the names KSP-100, KSP-101, KSP-102, KSP-103, KSP-104 and KSP-105 by the company Shin-Etsu, and - talc/titanium dioxide/alumina/silica composite powders such as those sold under the name Coverleaf .®' AR-80 by the company Catalyst & Chemicals,
  • silica powders for instance the porous silica microspheres sold under the name Silica Beads SB-700 sold by the company Myoshi, the products Sunsphere ® H51, Sunsphere ® H33 and Sunsphere ® H53 sold by the company Asahi Glass; the polydimethylsiloxane-coated amorphous silica microspheres sold under the name SA Sunsphere ® H-33 and SA Sunsphere ® H-53 sold by the company Asahi Glass;
  • nylon ® powders for instance Orgasol ® 4000 sold by the company Arkema, and
  • polymethyl methacrylate for instance Covabead ® LH85 sold by the company Wackherr
  • polymethyl methacrylate/ethylene glycol dimethacrylate for instance Dow Corning 5640 Microsponge ® Skin Oil Adsorber sold by the company Dow Corning, or Ganzpearl ® GMP-0820 sold by the company Ganz Chemical
  • polyallyl methacrylate/ethylene glycol dimethacrylate for instance Poly-Pore ® L200 or Poly- Pore ® E200 sold by the company Amcol
  • ethylene glycol dimethacrylate/lauryl methacrylate copolymer for instance Polytrap ® 6603 sold by the company Dow Corning
  • Polytrap ® 6603 sold by the company Dow Corning
  • - silicate particles such as alumina silicate
  • magnesium aluminium silicate particles such as saponite or hydrated magnesium aluminium silicate with a sodium sulphate sold under the trade name Sumecton ® by the company Kunimine; - the magnesium silicate, hydroxyethylcellulose, black cumin oil, marrow oil and phospholipids complex or Matipure ® from Lucas Meyer, and
  • Preferred matting agents that may be used according to the invention include a pumpkin seed extract, a rice or corn starch, kaolinite, silicas, talc, polyamide powders, polyethylene powders, acrylic copolymer powders, expanded acrylic copolymer microspheres, silicone resin microbeads and mixed silicate particles, and mixtures thereof.
  • These fillers may be any material capable of modifying wrinkles by virtue of its intrinsic physical properties and hiding them. These fillers may especially modify wrinkles via a tensioning effect, a covering effect or a soft-focus effect.
  • fillers examples include the following compounds:
  • silica microparticles for instance the Silica Beads ® SB150 and SB700 from Miyoshi with a mean size of 5 ⁇ m; the series-H Sunspheres ® from Asahi Glass, for instance Sunspheres H33, H51 with respective sizes of 3.5 and 5 ⁇ m;
  • silicone resin powders for instance the silicone resin Tospearl ® 145A from GE Silicone, with a mean size of 4.5 ⁇ m;
  • - wax powders for instance the paraffin wax particles MicroEase ® 114S from MicroPowders, with a mean size of 7 ⁇ m;
  • polyethylene powders especially comprising at least one ethylene/acrylic acid copolymer for instance the Flobeads ® EA 209 E from Sumitomo, with a mean size of 10 ⁇ m;
  • - talc/titanium dioxide/alumina/silica composite powders for instance those sold under the name Coverleaf AR-80 ® by the company Catalyst & Chemical;
  • - talc mica, kaolin, lauryl glycine, starch powders crosslinked with octenyl succinate anhydride, boron nitride, polytetrafluoroethylene powders, precipitated calcium carbonate, magnesium carbonate, magnesium hydrogen carbonate, barium sulphate, hydroxyapatite, calcium silicate, cerium dioxide and glass or ceramic microcapsules;
  • - spherical elastomeric crosslinked silicones for instance Trefil E-505C ® or E-506C ® from Dow Corning
  • - abrasive fillers which, via a mechanical effect, smooth out the skin microrelief, such as abrasive silica, for instance Abrasif SP ® from Semanez or nut or shell powders (for example of apricot or walnut, from Cosmetochem) .
  • the fillers with an effect on the signs of ageing are especially chosen from porous silica microparticles, hollow hemispherical silicone particles, silicone resin powders, acrylic copolymer powders, polyethylene powders, crosslinked elastomeric organopolysiloxane powders coated with silicone resin, talc/titanium dioxide/alumina/silica composite powders, precipitated calcium carbonate, magnesium carbonate, magnesium hydrogen carbonate, barium sulphate, hydroxyapatite, calcium silicate, cerium dioxide, glass or ceramic microcapsules, and silk fibres or cotton fibres, and mixtures thereof.
  • the filler may be a soft-focus filler.
  • the term "soft-focus” filler means a filler which in addition gives the complexion transparency and a hazy effect.
  • the "soft-focus” fillers have a mean particle size of less than or equal to 15 microns. These particles may be in any form and in particular may be spherical or non-spherical. These fillers are more preferably non-spherical.
  • the "soft-focus” fillers may be chosen from silica and silicate powders, especially alumina powder, powders of polymethyl methacrylate (PMMA) type, talc, silica/Ti ⁇ 2 or silica/zinc oxide composites, polyethylene powders, starch powders, polyamide powders, styrene/acrylic copolymer powders and silicone elastomers, and mixtures thereof.
  • silica and silicate powders especially alumina powder, powders of polymethyl methacrylate (PMMA) type, talc, silica/Ti ⁇ 2 or silica/zinc oxide composites, polyethylene powders, starch powders, polyamide powders, styrene/acrylic copolymer powders and silicone elastomers, and mixtures thereof.
  • talc with a number-average size of less than or equal to 3 microns for example talc with a number-average size of 1.8 microns and especially the product sold under the trade name Talc P3 ® by the company Nippon Talc, Nylon ® 12 powder, especially the product sold under the name Orgasol 2002 Extra D Nat Cos ® by the company Atochem, silica particles 1% to 2% surface-treated with a mineral wax (INCI name: hydrated silica (and) paraffin) such as the products sold by the company Degussa, amorphous silica microspheres, such as the products sold under the name Sunsphere, for example of reference H-53 ® by the company Asahi Glass, and silica microbeads such as those sold under the name SB-700 ® or SB-150 ® by the company Miyoshi, this list not being limiting.
  • exfoliants that may be used in rinse-out compositions according to the invention, examples that may be mentioned include exfoliants or scrubbing particles of mineral, plant or organic origin.
  • exfoliants or scrubbing particles of mineral, plant or organic origin include exfoliants or scrubbing particles of mineral, plant or organic origin.
  • polyethylene beads or powder, Nylon powder, polyvinyl chloride powder, pumice powder, ground apricot kernel or walnut husk, sawdust, glass beads and alumina, and mixtures thereof, may be used, for example.
  • Mention may also be made of Exfogreen ® from Solabia
  • peach kernel powder As abrasive fillers or exfoliants that are preferred according to the invention, mention will be made of peach kernel powder, apricot kernel powder, cranberry kernel powder, strawberry akene extracts and bamboo extracts.
  • the additional filler (s) used in the compositions according to the invention may represent preferably from 0.01% to 20% by weight and better still from 0.1% to 15%, and even better still, from 0.5 to 5% by weight relative to the total weight of the composition.
  • compositions according to the invention may comprise one or more additional cosmetic or dermatological active agents.
  • the additional active agents may in particular be chosen from moisturisers, agents for improving the barrier function, antioxidants, dermo-decontracting agents, anti-glycation agents, agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing their degradation, agents for stimulating fibroblast or keratinocyte proliferation and/or keratinocyte differentiation, agents for promoting the maturation of the horny envelope, NO- synthase inhibitors, peripheral benzodiazepine receptor
  • PBR PBR antagonists
  • agents for increasing the activity of the sebaceous glands agents for stimulating the energy metabolism of cells, tensioning agents, fat- restructuring agents, slimming agents, agents for promoting the cutaneous capillary circulation, calmatives and/or anti-irritants, sebo-regulators or anti-seborrhoeic agents, astringents, cicatrising agents, anti-inflammatory agents and anti-acne agents.
  • At least one active agent chosen from moisturisers agents for improving the barrier function, antioxidants, dermo-decontracting agents, anti-glycation agents, agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing their degradation, agents for stimulating fibroblast or keratinocyte proliferation and/or keratinocyte differentiation, agents for promoting the maturation of the horny envelope, NO- synthase inhibitors, peripheral benzodiazepine receptor
  • PBR PBR antagonists
  • agents for increasing the activity of the sebaceous glands agents for stimulating the energy metabolism of cells, fat-restructuring agents and agents for promoting the cutaneous capillary circulation for the area around the eyes.
  • At least one active agent chosen from sebo-regulating agents or anti-seborrhoeic agents, and astringents.
  • At least one active agent chosen from anti-acne agents, cicatrising agents and anti-inflammatory agents.
  • an active agent chosen from slimming active agents and active agents for promoting the cutaneous capillary circulation. Examples of such compounds are described hereinafter .
  • Moisturisers or humectants that may especially be mentioned include glycerol and derivatives thereof, urea and derivatives thereof, especially Hydrovance ® sold by National Starch, lactic acids, hyaluronic acid, AHAs, BHAs, sodium pidolate, xylitol, serine, sodium lactate, ectoin and derivatives thereof, chitosan and derivatives thereof, collagen, plankton, an extract of Imperata cylindra sold under the name Moist 24 ® by the company Sederma, acrylic acid homopolymers, for instance Lipidure-HM ® from NOF Corporation, beta-glucan and in particular sodium carboxymethyl beta-glucan from Mibelle-AG-Biochemistry; a mixture of passionflower oil, apricot oil, corn oil and rice bran oil sold by Nestle under the name NutraLipids ® ; a C-glycoside derivative such as those described in patent application WO 02/051828 and in particular C-
  • the moisturiser that will preferably be used is chosen from urea and derivatives thereof, especially Hydrovance ® sold by National Starch, hyaluronic acid, AHAs, BHAs, acrylic acid homopolymers, for instance Lipidure-HM ® from NOF Corporation, beta-glucan and in particular sodium carboxymethyl beta-glucan from Mibelle-AG-Biochemistry; a mixture of passionflower oil, apricot oil, corn oil and rice bran oil sold by Nestle under the name NutraLipids ® ; a C-glycoside derivative such as those described in patent application WO 02/051828 and in particular C- ⁇ -D- xylopyranoside-2-hydroxypropane in the form of a solution containing 30% by weight of active material in a water/propylene glycol mixture (60/40% by weight) such as the product sold by Chimex under the trade name Mexoryl SBB ® ; an oil of musk rose sold by Nestle; an extract of the microal
  • agents for improving the barrier function mention may be made especially of arginine, serine, an extract of Thermus thermophilus such as Venuceane ® from Sederma, an extract of the rhizome of wild yam
  • Relipidium ® from Coletica a chestnut extract such as Recoverine ® from Silab, a cedar bud extract such as Gatuline Zen ® from Gattefosse, sphingosines, for instance salicyloyl sphingosine sold under the name Phytosphingosine ® SLC by the company Degussa, a mixture of xylitol, polyxylityl glycoside and xylitan, for instance Aquaxyl ® from SEPPIC, extracts of Solanacea plants, for instance Lipidessence ® from Coletica, omega- 3 unsaturated oils such as musk rose oils, and mixtures thereof .
  • ceramides or derivatives thereof in particular ceramides of type
  • sphingoid-based compounds for instance N-2- hydroxypalmitoyldihydrosphingosine, having the INCI name: hydroxypalmitoyl sphinganine
  • sphingoid-based compounds glycosphingolipids, phospholipids, cholesterol and derivatives thereof, phytosterols, essential fatty acids, diacylglycerol, 4-chromanone and chromone derivatives, petroleum jelly, lanolin, shea butter, cocoa butter and PCA salts.
  • an extract of Thermus thermophilus an extract of wild yam rhizome (Dioscorea villosa) , a yeast extract, a chestnut extract, a cedar bud extract, arginine, serine, ceramides especially of type 3 and 5; and mixtures thereof.
  • Serine, arginine or a mixture thereof will preferably be used.
  • tocopherol and esters thereof in particular tocopheryl acetate; ferulic acid; serine; ellagic acid, phloretin, polyphenols, tannins, tannic acid, epigallocatechins and natural extracts containing them, anthocyans, rosemary extracts, olive leaf extracts, for instance those from the company Silab, green tea extracts, resveratrol and derivatives thereof, ergothioneine, N-acetylcysteine, an extract of the brown alga Pelvetia canaliculata, for instance Pelvetiane ® from Secma, chlorogenic acid, biotin, chelating agents, such as BHT and BHA, N, N' -bis (3, 4, 5-trimethoxybenzyl) ethylene- diamine and salts thereof; idebenone, plant extracts, for instance Pronalen BioprotectTM from the company Provital; coenzyme QlO, bioflavonoids, SOD
  • anti-ageing agents include DHEA and derivatives thereof, boswellic acid, rosemary extracts, carotenoids ( ⁇ -carotene, zeaxanthin and lutein) , cysteic acid, copper derivatives and jasmonic acid.
  • Preferred antioxidants that will especially be used include ferulic acid; serine; phloretin, an extract of pomegranate, biotin, chelating agents such as BHT, BHA, N, N' -bis (3, 4 , 5-trimethoxybenzyl) - ethylenediamine and salts thereof, caprylyl glycol, TotarolTM, a jasmine extract such as the product sold by Silab under the name Helisun ® ; hesperitin laurate such as Flavagrum PEG ® from the company Engelhard Lyon; an extract of Paeonia suffruticosa root, such as the product sold by the company Ichimaru Pharcos under the name Botanpi Liquid B ® .
  • chelating agents such as BHT, BHA, N, N' -bis (3, 4 , 5-trimethoxybenzyl) - ethylenediamine and salts thereof, caprylyl glycol, TotarolTM, a ja
  • Examples that may be mentioned include manganese gluconate and other salts, adenosine, alverine citrate and salts thereof, glycine, an extract of Iris pallida, a hexapeptide (Argeriline R from Lipotec) or sapogenins, for instance wild yam and the carbonyl amines described in patent application EP 1 484 052.
  • sapogenins examples include those described in patent application WO 02/47650, in particular wild yam, the diosgenin extracted especially from Dioscorea opposita or any extract naturally containing or containing after treatment one or more sapogenins (wild yam rhizome, agave leaf, which contains hecogenin and tigogenin, extract of Liliacea plants and more particularly yucca or smilax containing smilagenin and sarsapogenin, or sarsaparilla) or Actigen Y from the company Active Organics, or ginger.
  • sapogenins wild yam rhizome, agave leaf, which contains hecogenin and tigogenin, extract of Liliacea plants and more particularly yucca or smilax containing smilagenin and sarsapogenin, or sarsaparilla
  • Actigen Y from the company Active Organics, or ginger.
  • DMAE dimethyl MEA
  • extracts of sea fennel of rockrose, of helichrysum, of aniseed, of paracress
  • Gatuline ® an extract of Acmella oleracea
  • Preferred dermo-relaxing agents include adenosine, manganese gluconate, wild yam, sea fennel, glycine and alverine. 5. Anti-glycation agents
  • anti-glycation agent means a compound that prevents and/or reduces the glycation of skin proteins, in particular dermal proteins such as collagen .
  • Anti-glycation agents that may especially be mentioned include extracts of plants of the Ericacea family, such as an extract of blueberry (Vaccinium angustifolium or Vaccinium myrtillus) , for example the product sold under the name Blueberry Herbasol Extract PG by the company Cosmetochem, ergothioneine and derivatives thereof, hydroxystilbenes and derivatives thereof, such as resveratrol and 3, 3', 5,5'- tetrahydroxystilbene (these anti-glycation agents are described in patent applications FR 2 802 425, FR 2 810 548, FR 2 796 278 and FR 2 802 420, respectively) , dihydroxystilbenes and derivatives thereof, polypeptides of arginine and of lysine such as the product sold under the name Amadorine ® by the company Solabia, carcinine hydrochloride (sold by Exsymol under the name Austin ® ) , an extract of Helianthus annuus, for
  • Preferred anti-glycation agents include extracts of blueberry (Vaccinium myrtillus) and extracts of black tea.
  • Agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing their degradation mention may be made of those acting:
  • MMP metalloproteases
  • Mention may be made of: retinoids and derivatives, extracts of Medicago sativa such as Vitanol ® from Silab, an extract of Aphanizomenon flos- aquae (Cyanophyceae) sold under the name Lanablue ® by Atrium Biotechnologies, oligopeptides and lipopeptides, lipoamino acids, the malt extract sold by the company Coletica under the trade name Collalift ® ; blueberry or rosemary extracts; lycopene; isoflavones, derivatives thereof or plant extracts containing them, in particular extracts of soybean (sold, for example, by the company Ichimaru Pharcos under the trade name Flavosterone SB ® ) , of red clover, of flax or of kakkon; an extract of lychee such as the extract of ly
  • elastin and fibrillin molecules belonging to the elastin family (elastin and fibrillin), such as: retinol and derivatives, in particular retinyl palmitate; the extract of Saccharomyces cerevisiae sold by the company LSN under the trade name Cytovitin ® ; and the extract of the alga Macrocystis pyrifera sold by the company Secma under the trade name Kelpadelie ® ; a peptide extract of hazelnut such as the product sold by the company Solabia under the trade name Nuteline C ® ;
  • elastin degradation such as the peptide extract of seeds of Pisum sativum sold by the company LSN under the trade name Parelastyl ® ; heparinoids; and the N-acylaminoamides described in patent application WO 01/94381, such as ⁇ 2- [acetyl (3- trifluoromethylphenyl) amino] -3-methyl- butyrylamino ⁇ acetic acid, also known as N-[N-acetyl, N' - (3-trifluoromethyl) phenylvalyl] glycine, or N-acetyl- N- [ 3- ( trifluoromethyl) phenyl ] valylglycine or acetyl trifluoromethylphenylvalylglycine, or an ester thereof with a Ci-C ⁇ alcohol; an extract of rice peptides such as Colhibin ® from Pentapharm, or an extract of Phyllanthus emblica such as Emb
  • glycosaminoglycans such as the product of fermentation of milk with Lactobacillus vulgaris, sold by the company Brooks under the trade name Biomin Yoghurt ® ; the extract of the brown alga Padina pavonica sold by the company Alban Muller under the trade name HSP3 ® ; the Saccharomyces cerevisiae extract available especially from the company Silab under the trade name Firmalift ® or from the company LSN under the trade name Cytovitin ® ; an extract of Laminaria ochroleuca such as Laminaine ® from Secma; essence of Mamaku from Lucas Meyer, and an extract of Cress (Odraline ® from Silab) ;
  • fibronectin such as the extract of the zooplankton Salina sold by the company Seporga under the trade name GP4G ® ; the yeast extract available especially from the company Alban Muller under the trade name Drieline ® ; and the palmitoyl pentapeptide sold by the company Sederma under the trade name Matrixyl ® .
  • the active agents for stimulating epidermal macromolecules such as fillagrin and keratins
  • an active agent that stimulates the synthesis of dermal and/or epidermal macromolecules and/or that prevents their degradation chosen from agents for stimulating the synthesis of glycosaminoglycans, agents for inhibiting elastin degradation, agents for stimulating fibronectin synthesis, agents for stimulating the synthesis of epidermal macromolecules, and mixtures thereof, will be used.
  • an active agent that stimulates the synthesis of the glycosaminoglycans chosen from an extract of the brown alga Padina pavonica, an extract of Saccharomyces cerevisiae, an extract of Laminaria ochroleuca, essence of Mamaku, and an extract of cress, and mixtures thereof, will be used.
  • active agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing their degradation mention may be made of: synthetic peptides such as iamin, the biopeptide CL or palmitoyloligopeptide sold by the company Sederma; peptides extracted from plants, such as the soybean hydrolysate sold by the company Coletica under the trade name Phytokine ® ; rice peptides such as Nutripeptide ® from Silab, methylsilanol mannuronate such as Algisium C ® sold by Exsymol; folic acid; an extract of Medicago sativa (alfalfa) , such as the product sold by Silab under the name Vitanol ® ; a peptide extract of hazelnut, such as the product sold by the company Solabia under the name Nuteline C ® ; arginine; an extract of Aphanizomenon flos-aquae (Cyanophyceae) sold by the
  • the agents for stimulating fibroblast proliferation may be chosen, for example, from plant proteins or polypeptides, extracted especially from soybean (for example a soybean extract sold by the company LSN under the name Eleseryl SH-VEG 8 ® or sold by the company Silab under the trade name Raffermine ® ) ; an extract of hydrolysed soybean proteins such as Ridulisse ® from Silab; and plant hormones such as gibberellins and cytokinins; a peptide extract of hazelnut such as the product sold by the company Solabia under the name Nuteline C ® .
  • plant proteins or polypeptides extracted especially from soybean (for example a soybean extract sold by the company LSN under the name Eleseryl SH-VEG 8 ® or sold by the company Silab under the trade name Raffermine ® ) ; an extract of hydrolysed soybean proteins such as Ridulisse ® from Silab; and plant hormones such as gibberellins and cytokinins; a peptide extract of hazelnut such as
  • an agent that promotes keratinocyte proliferation and/or differentiation will be used.
  • the agents for stimulating keratinocyte proliferation that may be used in the composition according to the invention especially comprise adenosine; phloroglucinol, extract of Hydrangea macrophylla leaves, for instance Amacha Liquid E ® from Ichimaru Pharcos, a yeast extract such as Stimoderm® from CLR; the extract of Larrea divaricata such as Capislow ® from Sederma, mixtures of extracts of papaya, of olive leaves and of lemon, such as Xyleine ® from Vincience, retinol and esters thereof, including retinyl palmitate, phloroglucinol, the nut cake extracts sold by Gattefosse and the extracts of Solanum tuberosum such as Dermolectine ® sold by Sederma.
  • agents for stimulating keratinocyte differentiation are, for example, minerals such as calcium; sea fennel, a peptide extract of lupin, such as the product sold by the company Silab under the trade name Structurine ® ; sodium beta-sitosteryl sulphate, such as the product sold by the company Seporga under the trade name Phytocohesine ® ; and a water-soluble extract of corn, such as the product sold by the company Solabia under the trade name Phytovityl ® ; a peptide extract of Voandzeia substerranea such as the product sold by the company Laboratoires Serobi unanimouss under the trade name Filladyn LS 9397 ® ; and lignans such as secoisolariciresinol, and retinol and esters thereof, including retinyl palmitate.
  • minerals such as calcium
  • sea fennel a peptide extract of lupin
  • Structurine ® sodium beta
  • oestrogens such as oestradiol and homologues
  • cytokines agents for stimulating keratinocyte proliferation and/or differentiation.
  • plant proteins or polypeptides extracted especially from soybean (for example a soybean extract sold by the company LSN under the name Eleseryl SH-VEG 8 ® or sold by the company Silab under the trade name Raffermine ® ) ; an extract of hydrolysed soybean proteins such as Ridulisse ® from Silab; a peptide extract of hazelnut such as the product sold by the company Solabia under the name Nuteline C ® ; adenosine; phloroglucinol, a yeast extract such as Stimoderm ® from CLR; a peptide extract of lupin such as the product sold by the company Silab under the trade name Structurine ® ; a water-soluble corn extract, such as the product sold by the company Solabia under the trade name Phytovityl ® ; a peptide extract of Voandzeia substerranea
  • Agents for promoting the maturation of the horny envelope Agents that participate in the maturation of the horny envelope, which becomes impaired with age and induces a decrease in transglutaminase activity, may be used in the compositions of the invention. Examples that may be mentioned include urea and derivatives thereof and in particular Hydrovance ® from National Starch and the other active agents mentioned in L'Oreal patent application FR 2 877 220 (unpublished) .
  • the agent with an inhibitory action on NO synthase may be chosen from OPCs (procyanidol oligomers); plant extracts of the species Vitis vinifera sold especially by the company Euromed under the name "Leucocyanidines de raisins extra", or by the company Indena under the name Leucoselect ® , or finally by the company Hansen under the name "Extrait de marc de raisin”; plant extracts of the species Olea europaea preferably obtained from olive leaves and sold especially by the company Vinyals in the form of a dry extract, or by the company Biologia & Technologia under the trade name Eurol ® BT; and plant extracts of the species Ginkgo biloba, preferably a dry aqueous extract of this plant sold by the company Beaufour under the trade name "Ginkgo biloba ry standard", and mixtures thereof.
  • OPCs procyanidol oligomers
  • PBR Peripheral benzodiazepine receptor
  • Mention may be made, for example, of methyl dehydroj asmonate, hecogenin, hedione and 0-linoleyl-6D- glucose, and mixtures thereof.
  • Agents for stimulating the energy metabolism of cells may be chosen, for example, from biotin, an extract of Saccharomyces cerevisiae such as Phosphovital ® from Sederma, the mixture of sodium, manganese, zinc and magnesium salts of pyrrolidonecarboxylic acid, for instance Physiogenyl ® from Solabia, a mixture of zinc, copper and magnesium gluconate, such as Sepitonic M3 ® from SEPPIC, and mixtures thereof; a beta-glucan derived from Saccharomyces cerevisiae, such as the product sold by the company Mibelle AG Biochemistry.
  • biotin an extract of Saccharomyces cerevisiae such as Phosphovital ® from Sederma
  • the mixture of sodium, manganese, zinc and magnesium salts of pyrrolidonecarboxylic acid for instance Physiogenyl ® from Solabia
  • a mixture of zinc, copper and magnesium gluconate such as Sepitonic M3 ® from SEPPIC,
  • tensioning agent means compounds liable to have a tensioning effect, i.e. being able to make the skin taut.
  • the term “tensioning agent” generally means any compound that is soluble or dispersible in water at a temperature ranging from 25°C to 50 0 C at a concentration of 7% by weight in water or at the maximum concentration at which a medium of uniform appearance is formed and producing at this concentration of 7% or at this maximum concentration in water a shrinkage of more than 15% in the test described below.
  • the maximum concentration at which a medium of uniform appearance forms is determined to within ⁇ 10% and preferably to within ⁇ 5%.
  • medium of uniform appearance means a medium that does not contain any aggregates that are visible to the naked eye.
  • the tensioning agent is gradually added to the water with deflocculating stirring at a temperature ranging from 25°C to 50 0 C, and the mixture is then stirred for one hour.
  • the mixture thus prepared is then examined after 24 hours to see if it is of uniform appearance (absence of aggregates visible to the naked eye) .
  • the tensioning effect may be characterized by an in vitro shrinkage test.
  • a homogeneous mixture of the tensioning agent in water, at a concentration of 7% by weight or at the maximum concentration defined above, is prepared beforehand and as described previously.
  • the elastomer sample After drying for 3 hours at 22 ⁇ 3°C and 40 ⁇ 10% relative humidity RH, the elastomer sample has a shrunken width, noted L 3h , due to the tension exerted by the applied tensioning agent.
  • the tensioning agent may be chosen from: plant or animal proteins and hydrolysates thereof; polysaccharides of natural origin; mixed silicates; colloidal particles of mineral fillers; synthetic polymers; and mixtures thereof.
  • plant proteins and protein hydrolysates in particular of corn, rye, wheat, buckwheat, sesame, spelt, pea, bean, lentil, soybean and lupin
  • polysaccharides of natural origin especially (a) polyholosides, for example (i) in the form of starch derived especially from rice, corn, potato, cassava, pea, wheat, oat, etc.
  • colloidal particles of mineral fillers with a number-average diameter of between 0.1 and 100 nm and preferably between 3 and 30 nm, and chosen, for example, from: silica, silica-alumina composites, cerium oxide, zirconium oxide, alumina, calcium carbonate, barium sulphate, calcium sulphate, zinc oxide and titanium dioxide.
  • silica-alumina composite colloidal particles that may be used in the compositions according to the invention
  • examples that may be mentioned include those sold by the company Grace under the names Ludox AM, Ludox AM-X 6021, Ludox HSA and Ludox TMA, (e) synthetic polymers, such as polyurethane latices or acrylic-silicone latices, in particular those described in patent application EP-I 038 519, such as a polydimethylsiloxane grafted with propylthio (polymethyl acrylate) , propylthio (polymethyl methacrylate) and propylthio (polymethacrylic acid) , or alternatively a polydimethylsiloxane grafted with propylthio (polyiso- butyl methacrylate) and propylthio (polymethacrylic acid) .
  • synthetic polymers such as polyurethane latices or acrylic-silicone latices, in particular those described in patent application
  • Such grafted silicone polymers are especially sold by the company 3M under the trade names VS 80, VS 70 and LO21.
  • the tensioning agent will be present in the composition in an amount that is effective for obtaining the desired biological effect according to the invention.
  • the tensioning agent may be included in the composition according to the invention in a content ranging from 0.01% to 30% by weight of active material and preferably from 1% to 30% by weight of active material relative to the total weight of the composition .
  • active material is intended to exclude the medium in which the tensioning agent may be dissolved or dispersed in its commercial form, for example in the case of dispersions of colloidal particles .
  • agents that increase the expression of mechanoreceptors such as agents that increase the expression of integrins .
  • An example that may be mentioned is an extract of rye seed, such as the product sold by Silab under the name Coheliss ® .
  • fat- restructuring agents means agents capable of stimulating lipogenesis and of promoting adipocyte differentiation, thus making it possible to prevent or slow down the wasting of fat contained in the skin- supporting tissues, also known as "wasting of skin fat".
  • skin fat means the network of fat cells that forms the volumes on which the facial skin rests and is moulded.
  • fat-restructuring agents examples include an extract of black tea, such as the extract of fermented black tea sold by Sederma under the name Kombuchka ® , and an extract of Artemisia abrotanum, such as the product sold by Silab under the name Pulpactyl ® .
  • Slimming (lipolytic) agents that may especially be mentioned include caffeine, theophylline and its derivatives, theobromine, sericosine, asiatic acid, acefylline, aminophylline, chloroethyltheophylline, diprofylline, diniprophylline, etamiphylline and its derivatives, etofylline and proxyphylline; extracts of tea, of coffee, of guarana, of mate, of cola (Cola nitida) and especially the dry extract of guarana fruit (Paulina sorbilis) containing 8% to 10% caffeine; extracts of climbing ivy (Hedera helix) , of arnica (Arnica montana L) , of rosemary (Rosmarinus officinalis N), of marigold (Calendula officinalis) , of sage (Salvia officinalis L) , of ginseng (Panax gins
  • the active agent acting on the cutaneous capillary circulation may be used for preventing dulling of the complexion and/or to improve the appearance of the area around the eyes, in particular to reduce the shadows around the eyes. It may be chosen, for example, from an extract of maritime pine bark, for instance Pycnogenol ® from Bio prises, manganese gluconate (Givobio GMn ® from SEPPIC) , an extract of Ammi visnaga such as Visnadine from Indena, extract of lupin (Eclaline ® from Silab) , the protein coupling of hydrolysed wheat/palmitic acid with palmitic acid, such as Epaline 100 from Laboratoires Carilene, the extract of bitter orange blossom (Remoduline ® from Silab) , vitamin P and derivatives thereof, for instance methyl-4 esculetol sodium monoethanoate sold under the name Permethol ® by the company Sephytal, extracts of Ruscus, of
  • caffeine As preferred agents for promoting the cutaneous capillary circulation, mention will be made of caffeine, an extract of bitter orange blossom, an extract of black tea, rutin salts and an extract of the alga Corallina officinalis .
  • Calmatives or anti-irritants means a compound that can reduce the sensation of stinging, itching or tautness of the skin.
  • procyanidol oligomers vitamins E, B5 and B3, caffeine and derivatives thereof, pentacyclic triterpenes and plant extracts containing them, ⁇ -glycyrrhetinic acid and salts or derivatives thereof (stearyl glycyrrhetate, 3-stearoyloxyglycyrrhetic acid or glycyrrhetinic acid monoglucuronide) and also plants containing them (e.g.: Glycyrrhiza glabra) , oleanolic acid and salts thereof, ursolic acid and salts thereof, boswellic acid and salts thereof, betulinic acid and salts thereof, an extract of Paeonia suffruticosa and/or lactiflora, an extract of Lamlnarla saccharlna, extracts of Centella asiatica, Canola oil, bisabol
  • ⁇ -glycyrrhetinic acid and salts or derivatives thereof stearyl glycyrrhetate, 3-stearoyloxyglycyrrhetic acid or glycyrrhetinic acid monoglucuronide
  • plants containing them e.g.
  • Glycyrrhiza glabra ursolic acid and salts thereof; extracts of Centella asiatica, Canola oil, bisabolol; camomile extracts, allantoin; a mixture of extract of water lily blossom and of palmitoylproline, such as the product sold under the name Seppicalm VG ® by the company SEPPIC; Aloe vera, rose water, extract of mint, in particular of mint leaves, such as Calmiskin ® from Silab, filamentous bacteria such as Vitreoscilla filiformis as described in patent EP 761 204 and sold by Chimex under the name Mexoryl SBG ® , an extract of rose petals such as Rose Flower Herbasol ® extract from the company Cosmetochem, shea butter, a fermented extract of Alteromonas sold under the name Abyssine ® by the company Atrium Biotechnologies; spring water from the Vichy basin, such as waters originating from the Celestin, Chomel,
  • sibo-regulating or anti-seborrhoeic agents especially means agents capable of regulating the activity of the sebaceous glands.
  • Phellodendron extracts such as those sold under the name Phellodendron extract BG by the company Maruzen or Oubaku liquid B by the company Ichimaru Pharcos;
  • oligosaccharides of the alga Laminaria digitata such as the product sold under the name Phycosaccharide AC by the company Codif
  • - sugar cane extracts such as the product sold under the name Policosanol ® by the company Sabinsa
  • Cinchona succirubra bark such as the product sold under the name Red Bark HS by the company Alban Muller;
  • anti-seborrhoeic active agents include:
  • zinc salts such as zinc gluconate, zinc pyrrolidonecarboxylate (or zinc pidolate) , zinc lactate, zinc aspartate, zinc carboxylate, zinc salicylate and zinc cysteate;
  • the anti-seborrhoeic active agent is chosen from:
  • zinc salts such as zinc gluconate, zinc pyrrolidonecarboxylate (or zinc pidolate) , zinc lactate, zinc aspartate, zinc carboxylate, zinc salicylate and zinc cysteate; and preferably zinc pyrrolidonecarboxylate (or zinc pidolate) or zinc salicylate;
  • the anti-seborrhoeic active agent is, for example, present in a content ranging from 0.1% to 10% by weight, preferably from 0.1% to 5% by weight and preferentially from 0.5% to 3% by weight relative to the total weight of the composition.
  • Astringents means agents for combating the dilation of the sebaceous follicles.
  • extracts of mushroom pulp for instance Laricyl LS8865 ® from Cognis, extracts of Terminalia catappa and Sambucus nigra, for instance Phytofirm LS9120 ® from Cognis, extracts of gall nut, for instance Tanlex VE ® from Ichimaru Pharcos, aluminium hydroxychloride, centella extracts (e.g.
  • Plantactiv centella from Cognis dicetyl dimethylammonium chloride, for instance Varisoft 432 CG ® from Degussa, common horse chestnut extracts, mallow extracts, witch- hazel extracts, sweet almond extracts, marshmallow root extracts and linseed extracts, for instance Almondermin LS 3380 ® from Cognis, burdock extracts, nettle extracts, birch extracts, horsetail extracts, camomile extracts, for instance those sold under the name Extrapone 9 special ® by the company Symrise, skullcap extracts, European meadowsweet extracts (for example Cytobiol Ulmaire from Libiol) , a mixture of extracts of white ginger, of horsetail, of nettle, of rosemary and of yucca, for instance Herb extract B1348 ® from Bell Flavors & Fragrances, extracts of acacia, of elm, of white willow, of cinnamon, of birch and of meadowsweet, Panama sap
  • skullcap extracts European meadowsweet extracts, meadowsweet extracts, gentian extracts and burdock extracts, and mixtures thereof .
  • cicatrizing agents examples include: allantoin, urea, certain amino acids, for instance hydroxyproline, arginine, and serine, and also extracts of white lily (for instance Phytelene Lys 37EG 16295 from Indena) , a yeast extract, for instance the cicatrizing agent LS LO/7225B from Laboratoires Serobiiquess) , tamanu oil, extract of Saccharomyces cerevisiae, for instance Biodynes ® TRF ® from Arch Chemical, oat extracts, chitosan and derivatives, for instance chitosan glutamate, carrot extracts, artemia extract, for instance GP4G ® from Vincience, sodium acexamate, lavandin extracts, propolis extracts, ximeninic acid and salts thereof, rose hip oil, marigold extracts, for instance Souci Ami ® Liposolible from Alban Muller, horsetail extracts, lemon peel extracts, and also extracts
  • cicatrizing agents use will be made of arginine, serine, folic acid, tamanu oil, sodium acexamate, horsetail extracts and helichrysum extracts, and mixtures thereof.
  • Anti-inflammatory agents As particular anti-inflammatory agents that may be used according to the invention, mention may be made of cortisone, hydrocortisone, indomethacin, betamethasone, azelaic acid, acetaminophen, diclofenac, clobetasol propionate, folic acid; an extract of Eperua falcata bark, such as the product sold by the company Cognis under the name Eperuline ® ; an extract of Paeonia suffruticosa root, such as the product sold by the company Ichimaru Pharcos under the name Botanpi Liquid B ® ; and mixtures thereof.
  • Preferred anti-inflammatory agents are azelaic acid, folic acid, an extract of Eperua falcata bark, such as the product sold by the company Cognis under the name Eperuline ® ; an extract of Paeonia suffruticosa root, such as the product sold by the company Ichimaru Pharcos under the name Botanpi Liquid B ® ; and mixtures thereof.
  • the composition may also comprise at least one anti-acne active agent.
  • anti-acne active agent especially means any active agent that has effects on the specific flora of greasy skin, for instance Propionibacterium acnes (P. acnes) .
  • Antibactericidal active agents that may especially be mentioned include: - active agents and preserving agents with antimicrobial activity mentioned in patent application DE 103 24 567, which is incorporated into the present invention by reference, - Asiatic acid,
  • - glyceryl 2-ethylhexyl ether (INCI name: ethylhexylglycerine) , for example sold under the name Sensiva SC 50 ® by the company Shulke & Mayr, - glyceryl caprylate/caprate, for example sold under the name Capmul MCM ® by the company Abitec;
  • John's Wort extract obtained by supercritical CO2 extraction, such as the product sold under the name St. John's Wort CO2-TO extract ® by the company Flavex Naturextrakte,
  • - bearberry leaf extracts for instance the product sold under the name Melfade-J by the company Pentapharm; - lO-hydroxy-2-decanoic acid such as Acnacidol P ® from Vincience, sodium ursolate, azelaic acid, diiodomethyl p-tolyl sulphone such as Amical Flowable ® from Angus, malachite powder, zinc oxide such as Zincare ® from Elementis GMBH, octadecenedioic acid such as Arlatone dioic DCA ® from Uniqema; ellagic acid; 2, 4, 4' -trichloro- 2' -hydroxydiphenyl ether (or triclosan) , l-(3',4'- dichlorophenyl) -3- (4 ' -chlorophenyl) urea (or triclo- carban) , 3, 4, 4' -trichlorocarbanilide, 3',
  • betaines for instance the cocoyl betaine Genagen KB from Clariant, sodium lauryl ether sulphate, for instance Emal 270 D from Kao, decyl glucoside, for instance Plantacare 2000 UP, branched C12-13 dialkyl malates, for instance Cosmacol EMI, propylene glycol monoesters, for instance propylene glycol monolaurate, monocaprylate or monocaprate, lauryldimethylamine betaine, for instance Empigen BB/LS, and also polyquaternary ammoniums such as Quaternium-24 or Bardac 2050 from Lonza and those described in patent FR 0 108 283, and mixtures thereof.
  • an agent chosen from octoglycerine or octoxyglycerine, and 10-hydroxy- 2-decanoic acid, and mixtures thereof, will be used in the compositions of the invention.
  • anti-acne active agents may be added to the abovementioned anti-acne active agents.
  • Mention may be made especially of active agents with bacterial anti-adhesion effects or agents that act on the biofilm of bacteria to prevent them from multiplying .
  • phytanetriol and derivatives thereof as described in patent application EP 1 529 523, plant oils such as wheatgerm oil, calendula oil, castor oil, olive oil, avocado oil, sweet almond oil, groundnut oil, jojoba oil, sesame seed oil, apricot kernel oil, sunflower oil and macadamia oil, described in patent EP 1 133 979, or certain surfactants such as disodium cocoamphodiacetate, oxyethylenated (7 EO) glyceryl cocoate, 18-hexadecenyl succinate, octoxyglyceryl palmitate, octoxyglyceryl behenate, dioctyl adipate, PPG-15 stearyl ether, and the branched C12-C13 dialkyl tartrates described in patent EP 1 129 694, and mixtures thereof.
  • plant oils such as wheatgerm oil, calendula oil, castor oil, olive oil, avocado oil, sweet almond oil, groundnut oil
  • P. acnes or as active agents that act on the biofilm of bacteria to prevent them from proliferating, mention may be made of pentylene glycol, Nylon-66 (polyamide 66 fibres), rice bran oil, polyvinyl alcohol such as Celvol 540 PV alcohol ® from Celanese Chemical, rapeseed oil such as Akorex L ® from Karlshamns, and fructose derivatives, and mixtures thereof.
  • the anti-acne active agent may be present in a content ranging from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, relative to the total weight of the composition. According to the nature and/or the solubility of the abovementioned active agents, those skilled in the art will know how to select the most suitable embodiment according to the invention.
  • the cosmetic and/or dermatological active agents will be present in one of the compositions according to the invention in a content ranging from 0.001% to 20% by weight, relative to the total weight of the composition, preferably from 0.01% to 10%, even more preferentially from 0.5% to 5%, and more preferably from 0.1% to 1% by weight, relative to the total weight of the composition.
  • the contents of cosmetic and/or dermatological active agents may range from 1% to 50% by weight, relative to the total weight of the composition, preferably from 1% to 30% by weight, relative to the total weight of the composition .
  • Peelings are a well-known means for improving the appearance and/or the texture of the skin and/or of the scalp, especially for improving the radiance and homogeneity of the complexion and/or for reducing the visible and/or tactile irregularities of the skin, and in particular for improving the surface appearance of the skin, for attenuating actinic lentigo, acne or chickenpox marks, and also for preventing, attenuating or combating the signs of skin aging, and especially for smoothing out irregularities in the texture of the skin, such as wrinkles and fine lines.
  • the invention also relates to a cosmetic assembly comprising: a container delimiting at least one compartment, said container being closed by a closing member; and a composition as described above and placed inside said compartment .
  • the container may be in any suitable form. It may especially be in the form of a bottle, a tube, a jar, a case, a box, a sachet or a carton.
  • the closing member may be in the form of a removable stopper, a lid, a cap, a tear-off strip or a capsule, in particular of the type comprising a body attached to the container and a cover cap articulated on the body. It may also be in the form of a member for selectively closing the container, in particular a pump, a valve or a flat valve.
  • the container may be combined with an applicator.
  • the applicator may be in the form of a brush, as described, for example, in patent FR 2 722 380.
  • the applicator may be in the form of a block of foam or of elastomer, a felt or a spatula.
  • the applicator may be free (powder puff or sponge) or securely fastened to a rod borne by the closing member, as described, for example, in patent US 5 492 426.
  • the applicator may be securely fastened to the container, as described, for example, in patent FR 2 761 959.
  • the product may be contained directly in the container, or indirectly.
  • the product may be placed on an impregnated support, in particular in the form of a wipe or of a pad, and placed (individually or in plurality) in a box or in a sachet.
  • an impregnated support in particular in the form of a wipe or of a pad, and placed (individually or in plurality) in a box or in a sachet.
  • Such a support incorporating the product is described, for example, in application WO 01/03538, including correcting pencils.
  • the closing member may be coupled to the container by screwing.
  • the closing member and the container are coupled other than by screwing, in particular via a bayonet mechanism, by click-fastening, gripping, welding, bonding or by magnetic attraction.
  • click-fastening is intended to mean in particular any system involving the crossing of a bead or cord of material by elastic deformation of a portion, in particular of the closing member, followed by return to the elastically unconstrained position of said portion after crossing of the bead or cord.
  • the container may be at least partially made of thermoplastic.
  • thermoplastics mention may be made of polypropylene or polyethylene.
  • the container is made of nonthermoplastic material, in particular glass or metal (or alloy) .
  • the container may have rigid walls or deformable walls, in particular in the form of a tube or of a tubular bottle.
  • the container may comprise means for initiating or facilitating the distribution of the composition.
  • the container may have deformable walls so as to allow the composition to exit in response to a positive pressure inside the container, said positive pressure being caused by elastic (or nonelastic) squeezing of the walls of the container.
  • the container may be constituted of a carton with a base delimiting at least one housing containing the composition, and a lid, in particular articulated on the base, and capable of at least partially covering said base.
  • a carton is described, for example, in application WO 03/018423 or in patent FR 2 791 042.
  • the container may be fitted with a drainer arranged in the region of the aperture of the container. Such a drainer makes it possible to wipe the applicator and possibly the rod to which it may be securely fastened. Such a drainer is described, for example, in patent FR 2 792 618.
  • the graph of figure 1 shows that the composition has a critical wavelength ⁇ c equal to 349 nm.
  • composition 7 has a critical wavelength ⁇ c equal to 377 nm.
  • the phototype is expressed in the form of the ITA° angle calculated from the value of L * and b * of the skin .
  • I TA" (ATAN ( ( L * - 50 ) /b ) ) * 1 8 0 / 3 , 14 15 9 )
  • L * is the brightness of the skin
  • b * its yellow component obtained by conventional colorimetry measurements using a Minolta CR200 colorimeter.
  • ATAN is the arc-tangent function. This calculation, which is well known to those skilled in the art, is described in detail in Chardon A, Cretois I, Hourseau C: Skin colour typology and suntanning pathways. Int J Cosm Scie, 13, 191-208, 1991.
  • the skin types can be grouped together according to their ITA° in the following way: ITA° > 55°: very fair skin 41° ⁇ ITA° ⁇ 55°: fair skin 28° ⁇ ITA° ⁇ 41°: intermediate skin 10° ⁇ ITA° ⁇ 28°: matt skin -30° ⁇ ITA° ⁇ 10°: brown skin ITA° ⁇ -30°: black skin.
  • Minizones are delimited on the back and subjected to a UVA + UVB spectrum of 290 to 400 nm.
  • composition characterized by a critical wavelength value ( ⁇ c) of greater than 370 nm exhibits greater effectiveness for preventing browning than the composition which has a critical wavelength value ( ⁇ c) of less than 370 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un procédé cosmétique pour réguler le brunissement de la peau induit par un rayonnement UV, en particulier le brunissement d'une peau sombre, qui consiste à appliquer, sur la surface de la peau, au moins une composition comportant, dans un support de qualité cosmétique : a) au moins un agent de dépigmentation et b) au moins un système pour bloquer à la fois le rayonnement UVA et le rayonnement UVB; c) et facultativement au moins un agent kératolytique; ladite composition ayant une longueur d'onde critique λc de plus de 370 nm. La présente invention concerne également une composition comportant, dans un support de qualité cosmétique : a) au moins un agent de dépigmentation et b) au moins un système pour bloquer à la fois le rayonnement UVA et le rayonnement UVB; c) et facultativement au moins un agent kératolytique; ladite composition ayant une longueur d'onde critique λc de plus de 370 nm.
PCT/EP2009/064908 2008-12-17 2009-11-10 Procédé cosmétique pour réguler le brunissement de la peau induit par un rayonnement uv et compositions WO2010078985A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2011541256A JP2012512215A (ja) 2008-12-17 2009-11-10 Ｕｖ照射によって誘発される皮膚の褐変化を制御するための化粧方法、組成物
CN200980156894.0A CN102316844B (zh) 2008-12-17 2009-11-10 用于控制uv辐射诱导的皮肤晒黑的化妆方法和组合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0858710A FR2939669B1 (fr) 2008-12-17 2008-12-17 Procede cosmetique pour controler le brunissement de la peau induit par les radiations uv ; compositions.
FR0858710 2008-12-17
US14099708P 2008-12-29 2008-12-29
US61/140,997 2008-12-29

Publications (2)

Publication Number Publication Date
WO2010078985A2 true WO2010078985A2 (fr) 2010-07-15
WO2010078985A3 WO2010078985A3 (fr) 2011-03-10

Family

ID=40834328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/064908 WO2010078985A2 (fr) 2008-12-17 2009-11-10 Procédé cosmétique pour réguler le brunissement de la peau induit par un rayonnement uv et compositions

Country Status (4)

Country Link
JP (3) JP2012512215A (fr)
CN (1) CN102316844B (fr)
FR (1) FR2939669B1 (fr)
WO (1) WO2010078985A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBS20120092A1 (it) * 2012-06-04 2013-12-05 Paoli Ambrosi Gianfranco De Miscela per l'inibizione della biosintesi della melanina
JP2015505548A (ja) * 2012-01-31 2015-02-23 ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ 新規な光保護系
US20160067163A1 (en) * 2013-04-14 2016-03-10 Imke Meyer A Composition for Lightening Skin and Hair
WO2017070933A1 (fr) * 2015-10-30 2017-05-04 L'oreal Composition anhydre comprenant un dérivé diphénylméthane hydroxylé
EP3215495A4 (fr) * 2014-11-03 2018-05-02 Stella & Dot LLC Formulations et régimes de soin de la peau
WO2018159139A1 (fr) * 2017-02-28 2018-09-07 L'oreal Composition comprenant du résorcinol ou un dérivé de celui-ci
WO2021114024A1 (fr) * 2019-12-09 2021-06-17 L'oreal Composition pour éclaircir et/ou blanchir des matières kératiniques
US11266584B2 (en) 2012-07-13 2022-03-08 L'oreal Cosmetic composition comprising composite sunscreen particles
US11523976B2 (en) 2012-07-13 2022-12-13 L'oreal Composite pigment and method for preparing the same
WO2023097004A1 (fr) * 2021-11-24 2023-06-01 Jamrm, Llc Composition de dermabrasion anti-vieillissement et méthode d'application

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010015788A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Kosmetische Zubereitung mit einem Gehalt an Magnolienrindenextrakt zur Steigerung der Mikrozirkulation der haut sowie die Verwendung von Magolienrindenextrakt zur Herstellung topischer Zubereitungen zur Steigerung der Mikrozirkulation der Haut und/oder angiogenetisch wirksamer topischer Zubereitungen
DE102010015789A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Magnolienrindenextrakt und Alkylsulfaten
DE102010015790A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Magnolienrindenextrakt und Acylglutamaten
IT1401364B1 (it) * 2010-07-09 2013-07-18 Rottapharm Spa Composizioni dermocosmetiche per protezione solare
DE102011079239A1 (de) * 2011-07-15 2013-01-17 Henkel Ag & Co. Kgaa Sonnenschutzzusammensetzungen mit hohem Lichtschutzfaktor und angenehmer Sensorik
DE102011079238A1 (de) * 2011-07-15 2013-01-17 Henkel Ag & Co. Kgaa Emulsionsbasis für Sonnenschutzzusammensetzungen
JP6386911B2 (ja) * 2012-10-29 2018-09-05 ロート製薬株式会社 外用組成物
FR2999911A1 (fr) 2012-12-21 2014-06-27 Oreal Composition a base de trans-resveratrol ou d'un derive de trans-resveratrol.
CN103405379B (zh) * 2013-07-29 2015-11-04 广州丹奇日用化工厂有限公司 一种富含氨基酸的化妆品组合物及其在护肤品中的应用
FR3018190B1 (fr) * 2014-03-06 2016-03-18 Laboratoires M&L Composition cosmetique eclaircissante
FR3022775B1 (fr) * 2014-06-30 2018-03-02 L'oreal Composition anhydre comprenant un gelifiant lipophile, au moins deux charges distinctes l'une de l'autre et une phase grasse
AU2017208721B2 (en) * 2016-01-22 2021-07-29 Nexdius Limited Compositions that brighten skin, provide sun protection, and permit vitamin D production
WO2018000060A1 (fr) * 2016-06-30 2018-01-04 L'oreal Composition d'un écran solaire contre l'acné.
DE102016214214A1 (de) * 2016-08-02 2018-02-08 Parsa Haar- Und Modeartikel Gmbh Konjakschwamm zum Peeling und zur Massage der Haut
CN110787071B (zh) * 2019-12-16 2021-08-31 江南大学 一种紫外滤光纳米胶囊的制备方法
CN111557875B (zh) * 2020-06-02 2023-03-10 华熙生物科技股份有限公司 一种抗光污染、光损伤的护肤组合物及其制备方法和应用
CN116710054A (zh) * 2020-06-30 2023-09-05 欧莱雅 化妆品防晒组合物、化妆品防晒组合物的用途及用于制造化妆品防晒组合物的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396422A1 (fr) * 1989-05-05 1990-11-07 Unilever Plc Composition pour la peau
US5576354A (en) * 1990-02-14 1996-11-19 L'oreal Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate
US5750563A (en) * 1993-10-28 1998-05-12 Sansho Seiyaku Co., Ltd. Preparation for epidermis
WO2001070190A2 (fr) * 2000-03-23 2001-09-27 Unilever Plc Compositions cosmetiques
EP1323411A1 (fr) * 2001-12-07 2003-07-02 L'oreal Compositions cosmétiques antisolaires à base d'un mélange synergique de filtres et utilisations
US6699464B1 (en) * 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
WO2007077260A1 (fr) * 2006-01-05 2007-07-12 Symrise Gmbh & Co. Kg Formules de faible teneur en huile comprenant des dérivés de diphénylméthane
EP1952845A1 (fr) * 2007-01-26 2008-08-06 DSMIP Assets B.V. Utilisation d'un dérivé d'astaxathine à des fins cosmétiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6312501A (en) * 2000-05-23 2001-12-03 Procter & Gamble Skin care moisturizing and sunscreen compositions comprising organic particulatematerial
US6999464B2 (en) * 2001-08-28 2006-02-14 Axiowave Networks, Inc. Method of scalable non-blocking shared memory output-buffered switching of variable length data packets from pluralities of ports at full line rate, and apparatus therefor
FR2888112B1 (fr) * 2005-07-11 2008-02-22 Oreal Composition photoprotectrice comprenant une phase aqueuse et une cire apolaire de bas point de fusion
US20090130035A1 (en) * 2006-01-05 2009-05-21 Symrise Gmbh & Co. Kg Stabilized preparations comprising phenolic compounds and benzophenones
DE102007005093A1 (de) * 2007-01-25 2008-07-31 Beiersdorf Ag Kosmetische Zubereitung gegen Hautpigmentierungen

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396422A1 (fr) * 1989-05-05 1990-11-07 Unilever Plc Composition pour la peau
US5576354A (en) * 1990-02-14 1996-11-19 L'oreal Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate
US5750563A (en) * 1993-10-28 1998-05-12 Sansho Seiyaku Co., Ltd. Preparation for epidermis
WO2001070190A2 (fr) * 2000-03-23 2001-09-27 Unilever Plc Compositions cosmetiques
US6699464B1 (en) * 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
EP1323411A1 (fr) * 2001-12-07 2003-07-02 L'oreal Compositions cosmétiques antisolaires à base d'un mélange synergique de filtres et utilisations
WO2007077260A1 (fr) * 2006-01-05 2007-07-12 Symrise Gmbh & Co. Kg Formules de faible teneur en huile comprenant des dérivés de diphénylméthane
EP1952845A1 (fr) * 2007-01-26 2008-08-06 DSMIP Assets B.V. Utilisation d'un dérivé d'astaxathine à des fins cosmétiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIFFEY B L: "A METHOD FOR BROAD SPECTRUM CLASSIFICATION OF SUNSCREENS", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 16, no. 2, 1 January 1994 (1994-01-01), pages 47-52, XP009025202, ISSN: 0142-5463 cited in the application *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505548A (ja) * 2012-01-31 2015-02-23 ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ 新規な光保護系
WO2013182996A1 (fr) * 2012-06-04 2013-12-12 General Topics S.R.L. Mélange pour l'inhibition de la biosynthèse de la mélanine
ITBS20120092A1 (it) * 2012-06-04 2013-12-05 Paoli Ambrosi Gianfranco De Miscela per l'inibizione della biosintesi della melanina
EA030102B1 (ru) * 2012-06-04 2018-06-29 Эксалиа С.Р.Л. Смесь для ингибирования биосинтеза меланина
US11266584B2 (en) 2012-07-13 2022-03-08 L'oreal Cosmetic composition comprising composite sunscreen particles
US11523976B2 (en) 2012-07-13 2022-12-13 L'oreal Composite pigment and method for preparing the same
US20160067163A1 (en) * 2013-04-14 2016-03-10 Imke Meyer A Composition for Lightening Skin and Hair
EP3215495A4 (fr) * 2014-11-03 2018-05-02 Stella & Dot LLC Formulations et régimes de soin de la peau
WO2017070933A1 (fr) * 2015-10-30 2017-05-04 L'oreal Composition anhydre comprenant un dérivé diphénylméthane hydroxylé
KR102245422B1 (ko) * 2017-02-28 2021-04-27 로레알 레조르시놀 또는 그 유도체를 포함하는 조성물
US11154473B2 (en) 2017-02-28 2021-10-26 L'oreal Composition comprising resorcinol or derivative thereof
KR20190099501A (ko) * 2017-02-28 2019-08-27 로레알 레조르시놀 또는 그 유도체를 포함하는 조성물
WO2018159139A1 (fr) * 2017-02-28 2018-09-07 L'oreal Composition comprenant du résorcinol ou un dérivé de celui-ci
WO2021114024A1 (fr) * 2019-12-09 2021-06-17 L'oreal Composition pour éclaircir et/ou blanchir des matières kératiniques
EP4072510A4 (fr) * 2019-12-09 2023-09-06 L'oreal Composition pour éclaircir et/ou blanchir des matières kératiniques
WO2023097004A1 (fr) * 2021-11-24 2023-06-01 Jamrm, Llc Composition de dermabrasion anti-vieillissement et méthode d'application

Also Published As

Publication number Publication date
FR2939669A1 (fr) 2010-06-18
WO2010078985A3 (fr) 2011-03-10
FR2939669B1 (fr) 2011-03-25
CN102316844B (zh) 2015-06-17
JP2018048210A (ja) 2018-03-29
JP2016040334A (ja) 2016-03-24
CN102316844A (zh) 2012-01-11
JP2012512215A (ja) 2012-05-31
JP6535592B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
JP6535592B2 (ja) Ｕｖ照射によって誘発される皮膚の褐変化を制御するための化粧方法、組成物
JP5697838B2 (ja) 半結晶性ポリマーおよび中空ラテックス粒子を組み合わせる日光からの防護組成物
EP2234674B1 (fr) Émulsions antisolaires fluides huile dans eau contenant un tensioactif jumelé specifique et un copolymère réticulé d'acide méthacrylique et d'acrylate d'éthyle
US10173080B2 (en) Dehydroascorbic acid or monomeric, polymeric or isomeric derivative thereof and an amine for artificially coloring the skin
ES2439248T3 (es) Composición fotoprotectora fluida acuosa a base de un polímero de poliamida con terminación amida terciaria
US20090018200A1 (en) Composition containing a phenanthrenol
EP1847247B1 (fr) Compositions comprenant un dérivé diphényl-méthane hydroxylé
EP2370179B1 (fr) Composition photoprotectrice contenant un amidon gélifiant non modifié et des particules de polyamide
US20080226756A1 (en) Compositions comprising a c-glycoside compound
US20070248633A1 (en) Compositions containing a hydroxylated diphenylmethane compound, methods of use
WO2009098139A1 (fr) Composition cosmétique contenant un dérivé de dibenzoylméthane et un dérivé d'ester d'acide n-acylamino neutre particulier ; procédé de photostabilisation du dérivé de dibenzoylméthane
US20100150853A1 (en) Artificially coloring the skin with a carotene compound, a xanthophyll compound and a lipophilic green dye composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980156894.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748352

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11063891

Country of ref document: CO

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011541256

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 09748352

Country of ref document: EP

Kind code of ref document: A2